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  ABSTRACT 
 
INTERACTION OF BACILLUS ANTHRACIS EXOSPORIUM PROTEIN BCLA WITH 
COMPLEMENT FACTOR H AND SPORE PERSISTENCE IN THE LUNG 
 
Publication No--------- 
Sarah Ann Jenkins, M.S. 
Supervisory Professor: Yi Xu, Ph.D. 
 
  
Anthrax outbreaks in the United States and Europe and its 
potential use as a bioweapon have made Bacillus anthracis an 
interest of study. Anthrax infections are caused by the entry of B. 
anthracis spores into the host via the respiratory system, the 
gastrointestinal tract, cuts or wounds in the skin, and injection. 
Among these four forms, inhalational anthrax has the highest 
lethality rate and persistence of spores in the lungs of animals 
following pulmonary exposure has been noted for decades. However, 
details or mechanisms of spore persistence were not known. In this 
study, we investigated spore persistence in a mouse model. The 
results suggest that B. anthracis spores have special properties 
that promote persistence in the lung, and that there may be multiple 
mechanisms contributing to spore persistence. Moreover, recent 
discoveries from our laboratory suggest that spores evolved a 
sophisticated mechanism to interact with the host complement system. 
The complement system is a crucial part of the host defense 
mechanism against foreign microorganisms. Knowledge of the specific 
interactions that occur between the complement system and B. 
anthracis was limited. Studies performed in our laboratory have 
suggested that spores of B. anthracis can target specific proteins
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  such as Factor H (fH) of the complement system. Spores of B. 
anthracis are enclosed by an exosporium, which consists of a basal 
layer surrounded by a nap of hair-like filaments. The major 
structural component of the filaments is called Bacillus collagen-
like protein of anthracis (BclA), which comprises a central 
collagen-like region and a globular C-terminal domain. BclA is the 
first point of contact with the innate system of an infected host. 
In this study, we investigated the molecular details of BclA-fH 
interaction with respect to the specific binding mechanism and the 
functional significance of this interaction in a murine model of 
anthrax infection. We hypothesized that the recruitment of fH to the 
spore surface by BclA limits the extent of complement activation and 
promotes pathogen survival and persistence in the infected host. 
Findings from this study are significant to understanding how to 
treat post-exposure prophylaxis and improve our knowledge of spores 
with the host immune system.  
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  CHAPTER ONE: INTRODUCTION 
 
 Bacillus anthracis, once serving as the prototype for Robert 
Koch’s postulates regarding the causation of infectious disease, 
continues to generate concern as an agent of bioterrorism. The 
organism known to cause the disease, anthrax, is infrequent in the 
United States and other countries. Roughly 20,000 – 100,000 cases 
are reported worldwide. In December 2009, a previously healthy 24 – 
year old New Hampshire woman nearly died due to contact with 
contaminated drum skins [1]. In 2012, animal slaughter in an Indian 
tribal village led to human exposure and a fatality rate of 18% [2]. 
These cases and recent outbreaks of injectional anthrax in more than 
50 heroin users in the United Kingdom and Germany [3-6] have 
sustained the importance of this potentially lethal infection in 
humans.  
The natural hosts of B. anthracis are grazing herbivores. Human 
infections result from contact with B. anthracis via cuts or wounds 
in the skin, via the gastrointestinal tract, the respiratory system, 
and by injection. Among these four forms, inhalational anthrax is 
the most severe and has the highest lethality rate despite the 
appropriate antimicrobial agents and advanced supportive care 
available. The initial symptoms of inhalational anthrax resemble a 
common cold. Infected individuals can develop a mild fever, muscle 
aches, malaise, cough, and a sore throat. After a few days, severe 
breathing problems can develop leading to key pathological 
manifestations including edema, hemorrhage, mediastinal enlargement, 
and pleural effusions. Also, a key feature of inhalational anthrax 
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  is the prolonged presence of spores in the host lung after the 
initial exposure. The ability of B. anthracis spores to persist in 
the lungs of animals including non-human primates and mice has been 
well documented [7-9]. This is the basis for the prolonged 
antibiotic regimen (60 days) recommended by the United States 
Department of Health and Human Services for patients with pulmonary 
exposure to B. anthracis spores. However, the underlying mechanism 
for persistence remains unknown.  
Bacillus anthracis life cycle. B. anthracis exists in two 
forms, endospores and vegetative bacilli. Spores of B. anthracis 
initiate anthrax infections. They are metabolically inactive and 
resistant to harsh conditions including ionizing radiation, extreme 
temperatures, detergents, and hydrolytic enzymes. Spores can survive 
in the environment for extended periods of time. B. anthracis 
strains are highly monomorphic due to the fact of endospores having 
prolonged periods of dormancy and reduced genetic variation. 
Electron micrographs of endospores reveal that the spore anatomy is 
composed of multiple layers (Fig. 1). Generally, spores consist of a 
dehydrated cellular core, which houses the spore DNA protected by 
dipicolinic acid (DPA) and small acid-soluble spore proteins (SASP) 
[10]. The inner membrane is where the germination receptors are 
located. The core is membrane-bounded and surrounded by a 
peptidoglycan cortex and a protective coat [10]. Some spore-forming 
pathogens, including Bacillus cereus, Clostridium botulinum, 
Bacillus thuringeneis, and B. anthracis contain an outermost layer 
called the exosporium. This structure is not observed in the 
nonpathogenic, Bacillus subtilis spore. It was recently discovered  
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  that the outermost layer of the subtilis spore is the spore crust 
composed of proteins CgeA and CotZ [11]. The exosporium constitutes 
about 2% of the mass of the spores containing 50% protein, 20% 
lipid, 20% neutral polysaccharides, and 10% other components [12]. 
Proteins comprising the exosporium of the B. anthracis spore have 
received considerable attention because these molecules are strong 
candidates for vaccines and ligands for spore detection. Scanning 
electron microscopy images have revealed that the exosporium 
contains a paracrystalline basal layer and a hair-like nap. Several 
basal layer proteins, ExsFA/BxpB, BxpA, BxpC and ExsY have been 
identified [12-14]. A single protein called Bacillus collagen-like 
protein of anthracis (BclA) was found to be the main component of 
the hair-like nap (Fig. 1) [15].  
Germination is the process of spores becoming vegetative 
bacteria. In theory, the spore can remain in the spore state 
forever, until it encounters germinants, such as nucleosides and 
amino acids. Upon germination receptor activation, the core 
hydrates, causing an influx of water and an efflux of DPA, resulting 
in loss of heat resistance. Two lytic enzymes, CwlJ and SleB degrade 
the cortex. Eventually the coat and exosporium are displaced and 
growth of vegetative bacilli proceeds [16, 17]. Vegetative bacilli 
represent the pathogenic form of B. anthracis. Bacilli are rod-
shaped (typically 5 – 7µm in length) and grow in long chains [18]. 
Vegetative bacilli have typical Gram-positive features, including a 
thick peptidoglycan cell wall, an S-layer, and a capsule composed of 
poly-γ-D-glutamic acid required for virulence [19]. These vegetative 
cells secrete a three-protein exotoxin composed of a cell binding 
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  protein called protective antigen and two enzymes called lethal 
factor (LF) and edema factor (EF), which work together to impart 
their physiological effects in the host. EF is a calcium and 
calmodulin activated adenylate cyclase that converts intracellular 
adenosine triphosphate (ATP) to cyclic adenosine monophosphate 
(cAMP). By increasing cAMP levels, EF acts to disrupt water 
homeostasis, impede balance of intracellular signaling pathways, and 
impair neutrophil function [20]. LF is a zinc metalloprotease that 
cleaves mitogen activated protein kinase kinases (MEKs), which 
respond to a diverse array of external signals and regulate various 
cellular responses, including inflammatory and macrophage 
activation. LF can interfere with macrophage release of chemokines 
and cytokines, such as IFNγ and TNF-α and cause lysis of these cells 
[20, 21]. LF is also known to inhibit antigen presentation by 
dendritic cells abrogating expression of co-stimulating molecules 
and can trigger apoptosis in endothelial cells [21]. When vegetative 
bacteria are nutrient depleted, they undergo sporulation, the 
process from vegetative bacilli to a spore. Sporulation begins with 
asymmetric cell division resulting in a mother cell and an 
endospore. The process is guided by the transcription factor Spo0A 
and two sigma factors σE and σF [22]. Eventually the mother-cell is 
shed and the resulting spore is capable of surviving harsh 
environments, such as high temperature, pH, salinity, and even time 
[22]. 
Bacillus collagen-like protein of anthracis (BclA). BclA is the 
collagen-like surface glycoprotein of the B. anthracis spore. It was 
first isolated and identified as an exosporium structural protein by 
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  Sylvestre et al in 2002. With the use of immunogold electron 
microscopy and a monoclonal anti-spore antibody, Sylvestre’s group 
confirmed that BclA is a component of the hair-like projections on 
the exosporium [15]. The amino-terminal sequence of the purified 
protein led to identification of the corresponding gene in the B. 
anthracis genome sequence. The bclA gene encodes a 382 amino acid 
protein under the control of a sigma k dependent promoter [15] (Fig. 
2, A). It is synthesized approximately 4 hours after the entry into 
sporulation and is absent in vegetative cells indicating that it is 
a spore-specific protein [15]. BclA is considered the immunodominant 
antigen on the spore surface because a large majority of anti-spore 
antibodies react with this protein [12]. 
BclA structure. BclA is comprised of three domains (Fig. 2, B). 
A short N-terminal domain (NTD), which is proteolytically cleaved 
and anchors BclA to the basal layer of the spore [23]. Its most 
striking feature is a collagen-like region (CLR) composed of strain-
specific GXY repeats. It has been shown that the filament lengths of 
B. anthracis strains are directly proportional to the lengths of the 
CLRs [24]. The CLR region of BclA contains a 21-amino acid motif, 
(GDT)5(GDTGTT), which is repeated six times and contains different 
numbers of GPT repeats. The sequence GDTGTT present in the motif is 
unique to BclA [15] (Fig. 2, A). Two O-linked oligosaccharides have 
been identified in BclA, a 715kDa tetrasaccharide (anthrose) and a 
234kDa disaccharide. Studies show that anthrose is attached to the 
CLR of BclA, but that the disaccharide might possibly be linked to 
another region [25]. Similar to mammalian collagen, the CLR of 
anthracis can form a triple helix. Glycine residues occupy every  
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  third amino acid in the repeating GXY, which is a prerequisite for a 
triple helix formation [15]. The high content of prolines and 
threonines contribute to the stabilization of the triple helix. 
Furthermore, CLR sequences are more recently being described in 
prokaryotes, highlighting the importance of BclA protein in B. 
anthracis. The third domain of BclA is the C-terminal domain (CTD), 
which is the distal end of the filament. The CTD was shown to be 
important for trimer formation [26].  
BclA functions. The exosporium is likely to play multiple roles 
in the interaction of the spore with its environment. For B. 
anthracis, BclA has been shown to mediate spore entry into host 
cells. It was reported previously that uptake of spores by 
phagocytes (i.e. macrophages, possibly dendritic cells) involved the 
interaction between integrin Mac-1 (Cd11b/CD18) receptor, co-factor 
CD14, and BclA [27, 28]. Our group showed that entry of spores into 
epithelial cells was mediated by BclA and host cell receptor 
integrin α2β1 via a mechanism that required host complement protein 
C1q [29]. Other host cell interactions involving BclA or biological 
functions of BclA have not been described.  
Host immune responses to B. anthracis spores. In general, 
interactions between exosporium proteins and host components 
influence the ways in which spores can survive in the infected host. 
BclA is a good vaccine and/or antibody target because it is the 
first point of contact with the host immune response. While the 
spore surface does not have any typical pathogen associated 
molecular patterns, such as lipopolysaccharide, lipoteichoic acid, 
peptidoglycan, or flagellin, a number of studies indicated that B. 
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  anthracis spores are not “stealth” to host immune recognition. 
Spores are capable of activating TLR2 and MyD88 signaling [30] and 
inducing inflammatory cytokine production in both MyD88-dependent 
and independent manners [31, 32]. Interestingly, BclA did not play a 
role in the host immune recognition by spores [31]. Spores induced 
the secretion of IL-12 from CD11b+ cells and IFN-γ by activating 
natural killer cells [31, 33, 34]. We previously showed that spores 
are capable of initiating the classical complement pathway via a 
direct interaction between BclA and C1q [35].  
The complement system. The complement system is the major 
defense and clearance system against pathogens in the human host. It 
can be activated in three ways, classical, lectin, and alternative 
(Fig. 3) [36]. The classical pathway is antibody-dependent because 
it is initiated by IgM or IgG clusters. The main recognition 
molecule, C1q binds to immune complexes on microbial surfaces and 
initiates the classical complement system. In the lectin pathway, 
mannose-binding lectin and ficolins recognize carbohydrate patterns 
on microbial surfaces to activate complement. Unlike the other two 
pathways, the alternative pathway is initiated through the 
spontaneous hydrolysis of C3.  All three pathways are able to form a 
C3 convertase, which is important for the activation of C3 to cleave 
into C3a and C3b. Cleavage of C3 exposes a reactive short-lived 
thioester moiety in C3b, which can covalently attach to amines and 
carbohydrate groups on targeted surfaces [36]. C3b deposition leads 
to opsonization for phagocytosis by phagocytes. In the presence of 
an additional C3b, the C3 convertase can function as a C5 convertase 
cleaving C5 into C5a and C5b. C5b associates with complement  
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  components C6 – 9 to initiate the assembly of the membrane attack 
complex (MAC) that leads to complement-mediated lysis [36]. 
Importantly, the complement system releases anaphylatoxins (C3a and 
C5a) which are potent chemoattractants that mediate chemotaxis of 
neutrophils, monocytes, and macrophages to sites of complement 
activation, inflammation, and generation of cytotoxic oxygen 
radicals [36].  
Soluble and cell-bound complement regulators help to control 
complement attack on host cells. In the alternative pathway, 
activation in solution is mainly controlled by factor H (fH) and its 
truncated homolog, factor H-like protein 1 (FHL-1) (Fig. 3). FH is 
encoded by a single gene (HF1) located on human chromosome 1q32 
within the regulators of complement activation gene cluster (RCA) 
[37]. FHL-1 is the product of the alternative splicing of HF1. The 
liver constitutively produces fH, but synthesis can also occur in 
peripheral blood, lymphocytes, myoblasts, epithelial cells, 
endothelial cells, and many more cell types. FH plasma levels have 
been reported to vary from 110 – 615µg/ml [0.8 – 5µM] [37].  
Factor H protein and structure. FH is a very large glycoprotein 
(155kDa). It is composed of 20 repetitive units called “short 
complement regulators” (SCRs; Fig. 4) [38]. Each SCR is encoded by a 
single exon, with the exception of SCR2, which is encoded by exons 3 
and 4. SCRs are composed of 61 residues and joined by linkers that 
consist of 3 – 8 residues and are arranged in head-to-tail fashion 
[38]. Because of its large size, glycosylation, and presumed inter-
SCR flexibility there is no high-resolution crystal structure for 
full-length fH. However, 14 of 20 SCRs have been resolved by 
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  crystallography and nuclear magnetic resonance. SCRs were reported 
to have a globular structure with six-stranded anti-parallel beta 
sheets connected with loops and turns [38]. Among the SCRs the 
conserved residues consist of four cysteines, two prolines, one 
tryptophan, and several other glycines and hydrophobic residues 
(Fig. 4, B). SCRs 1 – 4 are attributed to playing a role in cofactor 
activity and decay acceleration function of fH (Fig. 4, A). There 
are three binding sites for C3b (SCRs 1 – 4, 12 – 14, and 19 – 20) 
in addition to the three binding sites for heparin (SCRs 7, 13, and 
19 – 20) [39, 40]. Sialic acid interacts at SCR 19 – 20. SCRs 7 – 11 
and 19 – 20 engage with C-reactive protein [39, 40] (Fig. 4, A).  
The consensus sequence of fH SCRs are also seen in other members of 
the RCA family including C4b-binding protein (C4BP), complement 
receptor type I (CD35), decay accelerating factor (CD55), membrane 
cofactor protein (CD46), and fH-related proteins [39].  
Factor H functions. FH mainly acts on C3 convertases (C3bBb) in 
the alternative pathway either by competing with Factor B for 
binding to C3b to accelerate the decay of the C3 convertase and 
preventing downstream cleavage events to occur or serves as a 
cofactor for Factor I-mediated cleavage of C3b to its inactivated 
form iC3b, which inhibits the amplification loop [41] (Fig. 3). 
Importantly, fH has the ability to recognize host-specific markers 
such as sialic acid or glycosaminoglycans, thereby contributing to 
self-recognition and prevention of self-attack. Microbes do not have 
these markers on their surfaces and therefore are typically more 
susceptible to complement attack.  
13 
	  Factor H deficiencies. There are a number of clinical 
implications that arise from aberrant fH activity due to the central 
role that fH plays in the regulation of complement. This is 
supported by clinical evidence showing that mutations or single 
nucleotide polymorphisms that affect fH recognition of host cells 
are associated with severe human diseases due to abnormal complement 
activation. In addition, observations in experimental animal models 
that have a deficiency in fH caused the animals to either die soon 
after birth or spontaneously develop diseases due to uncontrolled 
complement activation [37]. One such disease is called age-related 
macular degeneration (AMD), which is the leading cause of blindness 
in elderly people of European descent. A single amino acid variant 
in SCR 7 of fH has been strongly associated with a person’s risk of 
developing AMD [42]. Other mutations in Factor B and C3 have also 
been attributed to the developmental risk of this disease. In 
particular, the mutation in fH reduces the affinity of fH for host 
markers (e.g. heparin and CRP); therefore decreasing the regulation 
of fH on critical surfaces, such as the back of the eye [42]. This 
mutation leads to an increase in inflammatory responses within the 
macula of the retina and leading to AMD. FH deficiencies can also 
lead to two rare but severe kidney diseases called 
membranoproliferative glomerulonephritis type II (MPGN II; dense 
deposit disease) and atypical hemolytic uremic syndrome (uHUS).  
Both diseases manifest at a very young age. Point mutations in 
either the conserved cysteine residues in SCRs or in particular SCRs 
19 – 20 and autoantibodies that either neutralize fH or stabilize 
the C3 convertase lead to excessive complement activation and the 
14 
	  development of these diseases [42]. Current treatments for patients 
with these diseases include plasma infusion or plasma exchange 
therapy and renal transplantation.  
Factor H-Ligand interactions. FH interacts weakly with its 
ligands (µM ranges). Many of the fH-ligand interactions reported 
exhibit a salt dependence because they are formed through opposing 
interactions. In general, fH is known to undergo 5 – 14% self- 
association in plasma if no other factors influence this equilibrium 
[38]. Evidence of self-association has been provided mainly from 
ultracentrifugation analyses, x-ray scattering concentration 
dependencies [43], and mass spectrometry, which revealed fH dimers 
and trimers [38]. Interactions between pairs of SCRs 6/8 and 16/20 
are important for the formation of these fH oligomers. One of the 
most important fH-ligand interactions is fH and C3 fragments (C3b, 
C3c, and C3d). The interaction of fH with these C3 fragments is 
crucial for complement regulation. C3b binds to fH at SCRs 1 – 4, 6 
– 8, and 19 – 20. C3c binds at SCRs 12 – 14 and C3d binds at SCRs 19 
– 20 (Fig. 4, A). The affinity for binding to C3 fragments is about 
0.59 – 2.9µM [38, 44]. Also, the interactions of fH with polyanionic 
molecules (e.g. heparin, glycosaminoglycans, and sialic acid; Fig. 
4) are important. FH has a greater affinity to bind and attach to 
cells that express these specific markers. The affinity for binding 
is reported to be approximately 9.2nM [38, 44]. Other interactions 
of fH include binding to pentraxins (CRP and Pentraxin 3), apoptotic 
and necrotic cells (annexin-II, DNA, and histones), extracellular 
matrix proteins (fibromodulin, osteoadherin, and chondoradherin), 
and zinc, which causes fH to aggregate [44].  
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  Recruitment of Factor H by bacterial pathogens. Given 
complement’s central role as a host defense mechanism against 
invading microbes, it is not surprising that many microbes have 
evolved strategies to evade complement. Recent studies have reported 
microbial pathogens that are capable of recruiting fH [37]. The 
findings indicate that recruitment of fH is advantageous to the 
specific organisms. Potentially, microbes can recruit fH as a means 
to regulate and control the alternative pathway activation and evade 
the host defense mechanism. Binding of fH or FHL-1 proteins allows a 
direct and rapid inactivation of the newly formed C3b at the 
microbial surface. Generally, Gram-positive bacteria are protected 
from complemented-mediated lysis through their cell wall 
architecture, however; several Gram-positive pathogens, such as 
Staphylococcus aureus [45, 46], Group A streptococci [47-50], and 
Streptococcus pneumoniae [51-56] have all been shown to have the 
ability to bind fH. The best characterized is the PspC and Hic 
proteins of S. pneumoniae. Residues 38 – 158 of the N-terminus of 
the PspC protein are attributed to the interaction with SCRs 6 – 10, 
13 – 15, and 19 – 20 on fH [52-54]. By interacting with fH, S. 
pneumonia has been shown to increase adhesion to host cells, resist 
complemented-mediated lysis, and suppress phagocytosis [54-56]. Two 
fH-binding proteins have been described for S. aureus (SdrE and 
Sbi). The binding regions for SdrE with fH have not been identified. 
The interaction of Sbi with fH involves domains III/IV on protein 
Sbi, SCRs 19 – 20 on fH and requires C3b/C3d for binding [45]. For 
B. anthracis, the ability to bind to fH has not been reported.  
Knowledge of the dynamic interplay between pathogens and 
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  components of the complement cascade are crucial to understanding 
the mechanisms of microbial invasion and persistence in an infected 
host. Despite the importance, knowledge of the specific interactions 
that occur between the complement system and B. anthracis is 
virtually non-existent. Likewise, the biological consequences of 
such interactions remain unknown. Moreover, the retention of spores 
observed from pulmonary anthrax exposure poses a problem with post-
exposure prophylaxis. Despite this well-known phenomenon in 
inhalational anthrax, detailed information on how spores persist in 
vivo and factors contributing to persistence has been lacking.   
In this dissertation, I examined the characteristics and 
spatial distribution of spores, as well as their association with 
different types of host cells. The results suggested potential 
mechanisms for spore persistence. Additionally, I investigated the 
basis of fH binding to the B. anthracis spore surface and defined 
the consequences of this interaction, particularly in relation to 
spore persistence, a critical aspect of B. anthracis pathogenesis in 
a host. I hypothesize that the recruitment of fH to the spore 
surface by BclA limits the extent of complement activation and 
promotes pathogen survival and persistence in the infected host.  
If this model holds true, it will have significant 
contributions to the anthrax field. First, recruitment of fH by B. 
anthracis has not been reported. From the aspect of BclA-protein 
interactions, BclA is a novel ligand for fH. Second, fH is a major 
suppressor of complement activation. Hence, this study is likely to 
reveal a novel immune suppression mechanism of B. anthracis. Third, 
the idea that binding of fH and the presence of BclA is important 
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  for persistent infections is a novel hypothesis and can have broad 
implications for many other pathogens, as well as vaccine 
development.  
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  CHAPTER 2: BACILLUS ANTHRACIS PERSISTENCE IN VIVO 
 
INTRODUCTION 
 One of the characteristic features of inhalational anthrax is 
the prolonged presence of spores in the lungs after an initial 
exposure. Decades ago this observation was reported by many 
researchers who were able to recover dormant spores from the lungs 
of non-human primates [7] and mice [8, 9] weeks or months after 
initial exposure. Additionally, studies by Heine et al reported that 
even with weeks of antibiotic treatments mice challenged with 
virulent B. anthracis spores still contained a substantial amount of 
spores in their lungs after discontinuation of the antibiotic 
regimen [8]. Pertinent studies in our laboratory showed that mice 
treated daily with antibiotics after a lethal challenge of B. 
anthracis spores, contained spores in the lung similar to mice 
treated without antibiotics. These studies suggested that spore 
persistence was observed independent of the use of antibiotics. 
Furthermore, our earlier experiments compared persistence in A/J 
mice, which are known to be more susceptible to the Sterne strain of 
B. anthracis and BALB/c mice, which are reported to be a resistant 
strain [57]. We found that host susceptibility is not a factor in 
spore persistence. Other studies have shown a delayed onset of 
anthrax infections (e.g., 58 days after exposure) in exposed 
animals, and the persistence of spores in the lung was thought to be 
responsible for the delay [58]. Based on these studies, the current 
duration of antibiotic treatment recommended for people with 
pulmonary exposure to anthrax is 60 days.  
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   Some microbial pathogens are able to thrive in the host despite 
the antimicrobial activities or host defense system causing a 
persistent infection. Unfortunately, our knowledge about the basis 
of bacterial persistent infections is not adequate to effectively 
prevent and treat such infections. There are several mechanisms that 
are described for bacteria that are able to do just that. These 
mechanisms include suppression of host immune responses [59], 
modulation of complement activation [60], resistance to phagocytic 
killing [61, 62], adaptation to the intracellular environment or to 
the mucosal surfaces [63, 64], biofilm formation [65], and evasion 
of host adaptive immunity [66]. For B. anthracis, the mechanism for 
spore persistence in the lung has not been investigated but has been 
largely attributed to the dormant nature and resilience of spores. 
However, recent findings by our laboratory highlight the 
possibility that there may be factors and other properties of spores 
that contribute to spore persistence. Russell et al showed that 
spores were found inside epithelial cells in the mouse lung within 
hours after exposure to spores and that internalized spores survived 
inside lung epithelial cells [67, 68]. Thus the intracellular 
environment of lung epithelial cells can potentially be a niche for 
spores to persist. There has also been evidence for biofilm 
formation by B. anthracis, B. subtilis and other related species and 
the presence of spores within the biofilm [69]. Evasion of the host 
immune system by binding to complement regulators may potentially be 
one way spores may “hide” from the host defense system. Human 
pathogens, such as Staphylococcus aureus [45, 46], Streptococcus 
pneumoniae [51], and Streptococcus pyogenes [49, 50] have all been 
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  identified to bind complement regulator fH as an immune evasion 
tactic.  
In this study, we investigated spore persistence in mice over a 
period of up to eight weeks. The spatial distribution of spores and 
their association with different host cells were examined. We also 
compared B. anthracis spores with spores from a non-pathogenic B. 
subtilis strain to determine whether “spores” in general can remain 
in a host for extended periods of time. The contribution of uptake 
by host cells and anthrax toxins to spore persistence was also 
examined. The results suggest that B. anthracis spores possess 
special properties that promote their survival and persistence in 
the host.  
 
EXPERIMENTAL PROCEDURES 
Bacterial strains and spore preparation. B. anthracis Sterne 
strain 7702, its isogenic toxin-deficient mutant strain (Δlef), 
plasmid-free B. anthracis strain 9131 derived from Sterne Strain 
7702, and B. subtilis strain PY79 were provided by T. M. Koehler, UT 
Health, Houston, TX. Spores of these strains were prepared by 
culturing in PA media for 10 days at 30°C as described previously 
[67]. E. coli HB101 was grown in Luria Broth (LB) overnight at 37°C 
with shaking. The overnight cultures were washed three times with 
sterile Phosphate Buffered Saline (PBS) prior to inoculation into 
mice. Bacterial counts were determined by plating on LB agar plates 
and incubation overnight at 37°C.  
Mouse infections. All animal experiments were carried out 
according to procedures approved by the Institutional Animal Care 
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  and Use Committee, Texas A&M Health Science Center, Institute of 
Biosciences and Technology (IBT). BALB/c mice were originally 
purchased from the Jackson Laboratory and maintained in the IBT 
animal facility. For infection experiments, 6 – 8 weeks old and sex-
matched mice were used. Mice were inoculated with spores or E. coli 
by intranasal instillation (i.n.) as previously described [29]. 
Briefly, mice were anesthetized with avertin (0.3mg/g) by 
intraperitoneal injection (i.p.). Mice were then inoculated i.n. 
with 20µls of a sub-lethal dose of spores (LD50 was determined in 
pilot studies to be ~1.7 x 108 cfu/mouse for BALB/c mice). Mice were 
monitored twice daily. Mice mostly appeared healthy with no physical 
signs of distress or illness throughout the experiments. To 
determine the bacterial burden in various organs mice were 
euthanized by avertin overdose. Lungs, kidneys, spleen, trachea and 
nasopharynx were collected at indicated time points. The tissues 
were homogenized in sterile cold PBS plus D-alanine, pH 7.4 (1 ml 
final volume) using a tissue homogenizer. Bronchoalveolar lavage 
(BAL) fluids were collected by lavaging the lungs with sterile PBS 
twice. The homogenates and BAL fluids were either directly diluted 
and plated to determine the number of total viable bacteria or 
heated at 68°C for 1 hour (hr) and dilution plated to determine the 
number of heat-resistant spores.   
Isolation and immunofluorescence staining of crude lung cell 
suspension (CLCS). Lungs were harvested from mice at indicated time 
points and digested as previously described to obtain crude lung 
cells. The CLCS was stained using a previously described procedure 
with some modifications [67]. To stain for specific cell types and 
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  spores, cells in the CLCS were allowed to attach to poly-L-lysine 
coated coverslips and then blocked with PBS containing 5% goat 
serum. Anti-BclA antibodies (rabbit polyclonal antibodies raised 
against recombinant BclA, a spore surface protein, 1:100) was added 
to the cells and incubated for 2 hrs followed by secondary 
antibodies conjugated to Alexa Fluor 594 to detect extracellular 
spores. Cells were then permeabilized, blocked and incubated again 
with anti-BclA antibodies followed by secondary antibodies 
conjugated to Alexa Fluor 488 to detect both extracellular and 
intracellular spores. Epithelial cells were detected with a pan 
epithelial mouse monoclonal antibody (Clone C-11, Chemicon, 1:250) 
recognizing different isoforms (4, 5, 6, 8, 10, 13, and 18) of 
cytokeratin, an epithelial specific marker, followed by secondary 
antibodies conjugated to Alexa Fluor 350.  Anti-CD11c and anti-CD11b 
antibodies (1:250) were used to stain phagocytes in the CLCS and BAL 
fluids, respectively. Coverslips were mounted on slides using 
Fluorsave and viewed with a Zeiss Axiovert 135 microscope with the 
Axio Vision Software.  
 Histology and immunofluorescence staining of lung sections. 
This was done following a previously described procedure with slight 
modifications [67]. Briefly, lungs were harvested at indicated time 
points and fixed in 10% formalin. Embedding, sectioning and H&E 
staining were performed at the Breast Center Pathology Laboratory, 
Baylor College of Medicine, Houston, TX. To detect spores, lung 
sections were incubated in a solution containing anti-BclA 
antibodies (1:250) for 2.5 hrs followed by incubation with Alexa 
Fluor 594-conjugated secondary antibodies for 1 hr. Phalloidin Alexa 
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  Fluor 488 was used to stain F-actin. DAPI was used to stain the 
nuclei. Some lung sections were also stained with wheat germ 
agglutinin Texas Red 595 (1:1000) to detect the plasma membrane. All 
dilutions were made in PBS pH 7.4 containing 2.5% fetal bovine 
serum. Five slides per mouse at each time point were examined. Lung 
sections were viewed with a Zeiss Axiovert 135 fluorescence 
microscope with the Axio Vision Software and an LSM 510 confocal 
laser scanning fluorescent microscope with the LSM 4.0 software 
(Zeiss).  
 Statistical analysis. Statistical analysis was performed using 
the two-tailed Student’s t-test (Graph-Pad Prism 4.0).  
 
RESULTS 
The lung is the primary site for B. anthracis spore 
persistence. BALB/c mice were challenged intranasally (i.n.) with 
sub-lethal doses of spores (1.3 x 107 and 1.1 x 108) of B. anthracis 
Sterne strain 7702 (pXO1+, pXO2-). BALB/c mice are generally more 
resistant to the Sterne strain [57] and therefore provided us a 
model to assay for persistence of spores where mice can survive and 
remain physically healthy for weeks post-initial infection. The 
majority of mice in each group challenged appeared healthy and 
normal with no physical signs of distress or illness throughout the 
experiments. However, some mice died unexpectedly approximately a 
week after the initial exposure. To determine the condition of 
spores that went into the lungs for the i.n. challenge, we harvested 
the lungs of mice 1 hour after challenge and plated for spores and 
heat-sensitive vegetative bacilli (Time 0, Table 1). The results 
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  showed that ≥90% of the recovered bacteria were spores, suggesting 
that most of the organisms that went into the lungs initially were 
spores.   
Over a period of 8 weeks, the amount of vegetative bacilli and 
spores in different organs were evaluated. The results indicated 
that substantial amounts of bacteria were recovered from the lungs 
of mice at 2, 4 and 8 weeks post-inoculation (Fig. 5 and Table 1). 
Mice that were given ~108 spores contained on average 4.1 x 105 ± 9.7 
x 104 colony forming units (cfu) and 9.2 x 104 ± 2.3 x 104 cfu per 
lung at 2 and 4 weeks post-inoculation, respectively (Fig. 5 and 
Table 1). These numbers correspond to approximately 0.3% and 0.09% 
of the initial inoculum. Furthermore, approximately 94% (2wks) and 
50% (4wks) of the bacteria recovered from the lung were heat-
resistant, indicating they were dormant spores. Additionally, mice 
inoculated with ~107 spores contained on average 3.7 x 105 ± 6.5 x 
104, 2.3 x 104 ± 4.0 x 103, and 1.3 x 104 ± 6.0 x 103 cfu per lung at 
2, 4, and 8 weeks post-inoculation, respectively (Fig. 5 and Table 
1). The cfu numbers from mice infected with this dose represent 
3.3%, 0.23%, and 0.09% of the initial inoculum retained in mice 
lungs over time. We found that on average 56, 70, and 81% of 
bacteria recovered from 2, 4, and 8 weeks post-inoculum were heat-
resistant dormant spores. Heat-sensitive vegetative bacilli were 
also detected at all three time points, indicating that spore 
germination occurred in the lung although at a lower frequency. We 
observed decreases in the total bacteria and spore titers in the 
lung over the experimental period, suggesting a continuous host 
clearance process. The decrease in the lung bacterial burden from 2  
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  to 4 weeks was significant (~13 – 25 fold) and from 4 to 8 weeks was 
relatively moderate (Fig. 5 and Table 1).  
To investigate if the lung was the major organ for spore 
persistence we examined the bacterial burden in other tissues over 
the experimental time frame. The bacterial titers in the spleen and 
kidney at 2 and 4 weeks were significantly lower (approximately 103 – 
104 fold) than those in the lung (Fig. 6, A and B). Similarly, a low 
bacterial load was found in the spleen at 8 weeks (data not shown). 
Intranasal inoculation exposed the nasopharynx associated lymphoid 
tissue (NALT) to the spores. A previous report indicated that the 
NALT was among the first organs in which vegetative growth was 
observed following pulmonary exposure to spores [70]. We examined 
the bacterial burden in the nasopharynx, as well as, the trachea at 
2 and 4 weeks post-inoculation. Less than 550 cfu were recovered 
from the trachea and less than 220 cfu from the nasopharynx at 2 
weeks. Even lower numbers (240 and 17 bacteria) were recovered at 4 
weeks from the trachea and nasopharynx, respectively (Fig. 6). These 
numbers were significantly lower than those recovered from the lung 
at both time points. Therefore, despite the fact that in acute 
anthrax infections bacterial growth is observed in multiple organs, 
including the ones examined in the above experiments, as expected, 
only the lung is the primary site for spore persistence. 
B. anthracis has special properties that contribute to its 
ability to persist in mice. We next investigated whether the ability 
of B. anthracis spores to persist in the lung was due to special 
properties of B. anthracis or if the lung tolerates metabolically 
inactive spores in general. Therefore, we examined if spores from  
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  Bacillus subtilis could persist in the lung equally well as those 
from B. anthracis. Mice were inoculated i.n. with approximately 1.3 
x 107 7702 or B. subtilis strain PY79 spores. Lungs were harvested at 
2 and 4 weeks post-inoculation and evaluated for total viable 
bacteria and spores. At 2 weeks post-inoculation, significantly more 
spores were recovered from the lungs of B. anthracis-infected mice 
(2 x 105 ± 5 x 104 spores/lung) compared to those from the lungs of 
B. subtilis (2 x 104 ± 7 x 103 spores/lung; Fig. 7). Similarly, at 4 
weeks post-inoculation, mice inoculated with B. anthracis spores had 
approximately 13 fold more spores in the lungs compared to mice 
inoculated with B. subtilis spores (Fig. 7). These results suggest 
that B. anthracis spores are better at persisting in the mouse lung 
than B. subtilis spores. Mice were also inoculated with overnight 
cultures of E. coli HB101, a non-sporulating, non-pathogenic strain 
as a negative control. These mice had significantly fewer bacteria 
(<1250 bacteria at both time points) in the lung than those infected 
with B. anthracis and B. subtilis, respectively (Fig. 7). We also 
calculated the spore burden in the lung as a percentage of the 
initial inoculum. At 2 weeks, the percentages were approximately 
1.7%, 0.25% and 0.01% for mice infected with 7702, PY79 and E. coli, 
respectively. At 4 weeks, the percentages were approximately 0.15%, 
0.02% and 0.01% for the three strains, respectively. These results 
suggest that in addition to dormancy and resilience, B. anthracis 
spores may possess special properties (i.e., exosporium), which are 
absent in B. subtilis that facilitate their persistence in the lung. 
Association of spores with the lung epithelium, epithelial 
cells, and phagocytes. We next examined whether the persistent B.  
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  anthracis spores were tightly associated with the lung tissue or in 
the fluid lining the respiratory epithelium, the latter of which can 
be recovered in the bronchoaveolar lavage (BAL) fluid. The results 
showed that at both 2 and 4 weeks post-inoculation, there were 
significantly more total bacteria as well as spores in the lung 
tissues than in the BAL fluid, suggesting that spores preferentially 
associated with lung tissues (Fig. 8, A – D). The difference of 
spores recovered from the mouse lung tissue compared to the BAL in 
mice given ~107 spores was much more pronounced at 2 weeks post-
inoculation (17 fold more cfu) than at 4 weeks (6 fold more cfu) 
(Fig. 8, A and B). Mice given ~108 spores had approximately 5 – 6 
fold more cfu in their lung tissue than in their BAL at both 2 and 4 
weeks post-inoculation (Fig. 8, C and D). Interestingly, at 8 weeks 
post-inoculation more bacteria were recovered from the BAL than the 
lung tissue (data not shown). These results show for the first time 
that dormant heat-resistant spores primarily associate with the lung 
tissue.  
We further analyzed lung sections from infected mice to 
determine the location of spores in the lung. Lung sections were 
obtained from mice infected with B. anthracis spores at 2, 4, and 8 
weeks. Hematoxylin and eosin (H&E) staining was performed to observe 
the general pathology in the lung. Overall, there was minimal 
pathology observed in the lung (Fig. 9). The alveolar and small 
airway epithelium as well as blood vessels appeared intact. For the 
most part of the lung, we observed no signs of inflammation or 
lesions (Fig. 9, A, B, D, E, G and H). We occasionally observed 
isolated foci that had inflammatory infiltrates at both 2 and 4 
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  weeks (Fig. 9, C and F). At 8 weeks, the lungs were 
indistinguishable from the uninfected lung (Fig. 9, G – L). 
 To detect spores in the lung, immunohistochemistry was 
performed. Lung sections were stained with antibodies specific for 
the exosporium protein BclA on spores. Cells were stained with 
phallodin and DAPI to visualize F-actin and the nuclei, 
respectively. Alternatively, cells were stained with wheat germ 
agglutinin conjugants to outline the plasma membrane. Microscopic 
examination of the stained sections revealed that spores were 
present in the lung at all three time points. Spores were observed 
associated with the alveolar and the small airway epithelium as 
single spores rather than in clusters (Fig. 10, A – F).  
Additionally, spores were seen distributed relatively evenly 
throughout the lung tissue similar to what was reported previously 
[67, 68]. Some of the spores that associated with the airway and 
alveolar epithelium appeared intracellular. To determine if the 
latter group of spores was indeed intracellular, we analyzed the Z-
stacks of confocal images of 124 potential intracellular spores from 
2 and 4 weeks. Of these, 101 (81%) were surrounded by F-actin (Fig. 
11, A) or enclosed within the plasma membrane (Fig. 11, B) and 
therefore were likely to be intracellular.  We also observed spores 
located within lymphoid-like tissues, although infrequently (Fig. 
11, G). Positive antigen staining of either intact spores or spore 
fragments were observed in the alveolar space (Fig. 11, H), 
suggesting that inflammation was associated with the presence of 
dormant or germinating spores or spore fragments. Isolated foci 
displaying mild infiltration of lymphocytes were observed in the  
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  immunofluorescently labeled lung sections, consistent with the H&E 
stained sections. Spore association with alveolar phagocytes was 
also observed (Fig. 11, I).  
To investigate the specific cell types with which spores 
associated, crude lung cell suspensions (CLCS) were prepared from 
lungs harvested at 2 and 4 weeks post-inoculation. Epithelial cells 
in the CLCS were detected using anti-cytokeratin antibodies (Fig. 
12, A). Approximately 23% of the CLCS cells were cytokeratin-
positive, consistent with previous results [67].  Approximately 3.8% 
and 7.6% of epithelial cells examined were associated with spores at 
2 and 4 weeks, respectively. On average, the percentage ratio of 
intracellular and extracellular adhered spores relative to 
cytokeratin positive epithelial cells was 0.95 ± 0.4% and 2.78 ± 
1.1% at 2 weeks, and 1.9 ± 0.3% and 5.7 ± 1.1% at 4 weeks, 
respectively (Fig. 12, B). Thus, spores associated with lung 
epithelial cells both extracellularly and intracellularly with the 
majority being extracellular. The CLCS also contained lung dendritic 
cells and residual alveolar macrophages that were not removed by 
lavage. To determine spore association with these phagocytes we 
stained the CLCS using anti-CD11c antibodies. Multiple spores were 
often seen inside these phagocytes (Fig. 12, C). Approximately 4.1% 
and 3.3% of CD11c+ cells contained spores at 2 and 4 weeks, 
respectively (Fig. 12, D). We also stained the BAL fluids with anti-
CD11b antibodies and observed approximately 14.8% and 4.5% of CD11b+ 
cells contained spores at 2 and 4 weeks, respectively (Fig. 12, E 
and F). Many of the phagocytes appeared to be packed with spores 
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  however, making accurate enumeration of the intracellular spores 
difficult.  
The anthrax toxins are not involved in spore persistence in the 
lung. Minimal inflammation observed in the lung from the H&E stained 
sections suggested that there was a subdued immune response in the 
presence of spores. B. anthracis lethal factor (LF) is a Zn2+-
dependent metalloprotease that cleaves mitogen-activated protein 
kinase kinases (MEKs) and plays an important role in suppressing the 
host immune responses during anthrax infections [71]. We observed a 
low level of spore germination in the lung during the studies 
described above. LF was reported to be secreted shortly after spores 
germinate [72]. We investigated the possibility that LF secreted by 
the germinated spores suppressed the immune response and contributed 
to spore persistence in the lung. We compared the persistence of 
spores from the Sterne strain 7702 with that from the isogenic LF-
deficient strain (Δlef) [73] as well as a plasmid-free 7702 Sterne 
strain 9131, which does not produce any anthrax toxins. We did not 
observe any significant difference in either the total bacteria or 
the spore counts between the three strains at 2 or 4 weeks post-
inoculation (Fig. 13, A and B), indicating that the anthrax toxins 
do not play a role in the persistence of spores in the mouse lung. 
 
DISCUSSION 
The ability to recover B. anthracis spores from the lungs of 
animal hosts weeks or months after the initial pulmonary exposure 
has been known for decades. For this reason, a 60-day antibiotic 
regimen is recommended for people with pulmonary exposure to spores  
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  [8, 9, 58].  However, beyond this knowledge detailed information on 
how spores persist in vivo and factors contributing to persistence 
was lacking. Here, we investigated the characteristics and spatial 
distribution of spores in mice as well as the association of spores 
with different types of host cells for up to 8 weeks. We also 
compared the persistence between spores of B. anthracis and B. 
subtilis. The results provided insights into the potential 
mechanisms underlying spore persistence, as discussed below. 
It has been reported that during late stages of acute 
inhalational anthrax infections large amounts of vegetative bacilli 
of B. anthracis were present in multiple organs, including the 
liver, kidney, lymphoid tissues, and even the brain, presumably via 
hematogenous spread [9, 70].  Results from the current study suggest 
that chronic persistence of spores in vivo exhibits a different 
pattern of tissue distribution. The lung is the primary site for 
spore persistence.  Interestingly, the number of spores in the NALT 
is orders of magnitude less than that in the lung despite that 
during a pulmonary exposure the NALT is also exposed to spores. 
Furthermore, previous studies in a mouse model for acute 
inhalational anthrax infections showed the detection of vegetative 
growth of B. anthracis in the NALT within hours of exposure to 
spores [70]. These results raise the possibilities that the lung 
appears to either “tolerate” spores better than the NALT, and/or 
discourage spore germination, and that the process of dissemination 
from the lung to other organs perhaps provides the necessary 
environmental cues or conditions for spores to germinate and become 
vegetative bacilli.   
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  The majority of recovered bacteria in the lung were heat-
resistant spores. Additionally, heat-sensitive bacilli were detected 
at all time points in the lung, but at significantly lower amounts 
compared to spore titers. This suggests that spore germination 
occurs although at a lower level during persistent infections. This 
can potentially be a cause for recurrent infections. In fact, a 
small number of mice succumbed to infection during the time course 
experiments; however these mice were not included in the analyses. 
It is possible that germination may occur inside host cells as a 
number of previous studies suggested intracellular germination using 
in vitro cultured cells [68, 74, 75]. The possibility that spores 
germinate extracellularly in the lung at a low frequency cannot be 
excluded either. In acute infections, different groups have 
investigated the site of spore germination after pulmonary exposure. 
Findings by Glomski et al [70] and Ross [76] indicated that spore 
germination occurred in organs other than the lung. However, studies 
by Sanz et al utilizing a Sterne strain that specifically expressed 
bioluminescence only upon germination reported germination proceeded 
in the lung [77]. The use of different bacterial/mouse strains 
and/or experimental methodologies utilizing different spore doses 
could have contributed to the different conclusions [70]. We also 
observed some spores in the other organs examined; however, the 
titers are orders of magnitude lower than those in the lung. These 
spores presumably spread to the distal organs via phagocytic cells.    
The next question is where in the lung spores persist. The 
bacterial burden in the BAL fluids and in the lavaged lung tissues 
suggest that the majority of persistent B. anthracis spores appeared 
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  to be tightly associated with lung tissues, as they could not be 
readily removed by lavage. Further examination of thin sections of 
the lung revealed that the spores adhered to the alveolar and airway 
epithelium and some were inside the cells lining the epithelium. 
This was further corroborated by immunofluorescence staining of lung 
cells harvested from the infected lungs. Differential 
immunofluorescence staining of lung epithelial cells indicated that 
there were more extracellularly adhered spores than intracellular 
ones.  This suggests that adherence to the lung epithelium may be an 
important mechanism for spores to persist in the lung. Residing in 
an intracellular niche of lung epithelial cells may be a secondary 
mechanism. The results also indicated that epithelial cells were not 
the only cell type that spores associated with. We observed spores 
inside CD11b+ and CD11c+ cells at both 2 and 4 weeks, and most of the 
spores appeared intact. The results in Fig. 8 indicated that viable 
spores were recovered from the BAL fluids at 2 and 4 weeks. These 
results suggest that spores may be viable inside the phagocytes, 
consistent with previous reports that spores were able to survive 
inside phagocytic cells [78]. Therefore, it is possible that the 
intracellular environment of phagocytic cells is a niche for spore 
persistence. On the other hand, multiple groups with somewhat 
controversial results have investigated the fate of phagocytosed B. 
anthracis spores. Spores are thought to germinate inside 
macrophages. Some of the studies reported replication of vegetative 
bacilli inside macrophages [72, 75, 79], while others showed killing 
of germinated spores and vegetative bacilli by macrophages [80-82]. 
Therefore, recovery of viable spores from phagocytes does not 
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  exclude the possibility of phagocytic killing of germinated spores 
and vegetative bacilli. The finding that total bacteria and spore 
titers in the lung significantly decreased over the experimental 
period, while the titers in other organs examined remained very low 
suggested a continuous host clearance process. Therefore, it is also 
possible that the spore-bearing CD11b+ and CD11c+ cells we observed 
reflect a part of the clearance process. 
We investigated if the ability to persist in the lung could be 
a general phenomenon of Bacillus spores, i.e., if spores from other 
species of Bacillus could also persist in the lung. The 
significantly lower bacterial/spore burden in the lungs of mice 
exposed to spores of a B. subtilis strain suggests that B. anthracis 
spores possess special properties that promote their survival and 
persistence in the lung. Moreover, it would be interesting to 
investigate if other exosporium-containing spores (e.g. B. cereus) 
could persist in the host in comparison to 7702 spores. B. subtilis 
spores are known to share a similar coat protein profile as that of 
B. anthracis spores but lack an exosporium which is present on the 
latter [83]. The exosporium is the outermost integument of B. 
anthracis spores and is composed of 20 – 30 proteins and 
glycoproteins [12, 14, 84]. It is possible that specific exosporium 
components contribute to B. anthracis spore persistence in the lung. 
BclA, a major component of the B. anthracis exosporium and absent in 
B. subtilis spores, was shown in a previous study to interact with 
surfactant protein C [85]; however the biological function of this 
interaction is unclear. It was previously shown that surface 
components on B. anthracis spores were sufficient to mediate spore 
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  adherence and entry into epithelial cells [68] and that B. subtilis 
spores were much poorer at adherence or entry into host cells [86]. 
It was reported that entry of B. anthracis spores into epithelial 
cells was mediated by the spore surface glycoprotein BclA and host 
cell receptor integrin α2β1 via a novel mechanism that requires 
complement component C1q as a bridging molecule [29]. Spores from a 
BclA deletion mutant (ΔbclA) showed decreased entry into epithelial 
cells compared to spores from the isogenic parent strain [29]. 
However, other studies reported a different role for BclA that it 
reduces spore entry into non-phagocytic host cells [27, 87]. One of 
the factors contributing to the discrepancy may be the germination 
status of spores in the assays. It seems that if spores remain 
dormant, BclA plays an important role in host cell entry via the 
BclA-C1q-α2β1 pathway. However, if spores are allowed to germinate 
in the assay media, the presence of BclA appeared to be a 
disadvantage in host cell entry [29]. As the majority of spores 
remain dormant in the host lung, results from dormant spores are 
likely to be more relevant to the in vivo situation. Studies to 
investigate the role of BclA in spore persistence in vivo are 
currently underway in our laboratory.  
Evans et al. reported that a bacterial lysate could induce 
innate resistance to infections caused by pulmonary exposure to B. 
anthracis spores. The authors further demonstrated that lung 
epithelial cells rather than macrophages or neutrophils were 
responsible for the induced resistance [88]. This demonstrates that 
the lung epithelium is an important player in the host defense 
against infections by B. anthracis spores. It is conceivable that in 
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  addition to mediating adherence and entry, interactions between 
exosporium components and the lung epithelium may also influence the 
host immune responses in a way that favors the survival of spores in 
the lung. We are currently carrying out studies to investigate the 
precise role of specific exosporium components in spore persistence. 
The very mild inflammation and pathology observed in the lung 
is also indicative of a subdued immune reaction to B. anthracis 
spores.  While the spore surface does not have any typical pathogen-
associated molecular patterns, such as lipopolysaccharide, 
lipotechoic acid, peptidoglycan, or flagellin, a number of studies 
indicated that B. anthracis spores are not “stealth” to host immune 
recognition. Spores are capable of activating Toll-like receptor 2 
and MyD88-dependent signaling [30], inducing inflammatory cytokine 
production in both MyD88-dependent and independent manners [31, 32], 
activating natural killer cells [33, 34] and initiating the 
classical complement pathway via a direct interaction between the 
exosporium component BclA and C1q [35]. These findings from the 
literature suggest that the subdued immune response may be due to an 
active immune evasion/suppression mechanism of B. anthracis rather 
than passive inactivity of the spores. We demonstrated that the 
anthrax toxins, in particular the lethal factor, a major immune 
suppressor of B. anthracis, did not play a role in spore persistence 
in the lung. This implies that B. anthracis exosporium components 
may have immune suppression properties. We are currently 
investigating this possibility.  
In summary, the results described in this study suggest that 
there are likely multiple mechanisms contributing to spore 
47 
	  persistence in the mouse lung. Association with the lung epithelium 
and immune suppression/evasion are two potential mechanisms. The 
results also suggest that spore surface components play important 
roles in mediating persistence. The work presented here has provided 
a foundation for further studies to elucidate the molecular 
mechanisms responsible for spore persistence. Understanding the 
mechanisms of persistence may potentially provide clues for 
developing more effective therapeutic regimens for anthrax 
infections and have implications for other persistent or chronic 
infections in general. 
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  CHAPTER 3: BCLA MEDIATES FACTOR H BINDING TO THE SURFACE OF SPORES 
 
INTRODUCTION 
 Factor H (fH) is a key suppressor of the alternative pathway of 
complement. It serves as the major cofactor for factor I, which 
mediates cleavage of C3b to its inactivated form (iC3b) and other 
smaller fragments. FH also accelerates the decay of C3 convertase 
(C3bBb) further inactivating complement activation and the 
amplification loop. The ability of fH to recognize specific markers 
on host cells is extremely important for limiting complement-
mediated immune responses to self-surfaces. For microbial pathogens, 
which do not contain these specific markers, acquiring these host 
complement regulators on their surfaces is crucial for host immune 
evasion.  
 The number of bacterial pathogens that are capable of 
recruiting fH has been growing. Studies have identified specific fH 
binding proteins for several pathogens including, Sbi and SdrE 
protein in Staphylococcus aureus [45, 46], M-related proteins and 
Scl1 protein in Group A streptococci [49, 50, 89], PspC protein in 
Streptococcus pneumonia [51], CRASP and OspE proteins in Borrelia 
species [90-92], FhbB protein in Treponema denticola [93], and Yad A 
and Ail proteins in Yersinia enterocolitica [94]. Even proteins from 
fungi [95, 96], parasites [97, 98], and viruses [99-101] have been 
reported to recruit fH. For B. anthracis, interaction with fH has 
not been reported. 
Spores of B. anthracis are generally thought to be resistant to 
innate immune defenses due to multiple extracellular layers and coat 
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  proteins that likely react with and detoxify chemical agents [10]. 
In general, B. anthracis spores contain an outermost layer called 
the exosporium, which is comprised of a hair-like nap predominantly 
consisting of a single surface protein called, Bacillus collagen 
like protein of anthracis (BclA). BclA is a 19.7 – 37kDa protein 
that is encoded chromosomally [15]. BclA protein is organized into 
three domains. The N-terminal (NTD; 40 amino acids) and the C-
terminal (CTD; 132 amino acids) domains are conserved among strains 
of B. anthracis [15]. Studies reported that cleavage of the NTD is 
required for efficient attachment of BclA to the exosporium basal 
layer [23]. The CTD is predicted to form an all beta structure with 
a jelly-roll topology; a similar fold as the TNF-like family of 
proteins (e.g. C1q, collagen VIII and X) [85]. In addition, the CTD 
contributes to trimer formation of the BclA protein and forms the 
distal end of each exosporium filament [26]. The third domain is the 
collagen-like region (CLR). The CLR is highly polymorphic among B. 
anthracis strains displaying a diverse number and organization of 
GPT repeats in the amino acid sequence [15]. The CLR, similar to 
mammalian collagen, forms a triple helix. By being the 
immunodominant antigen and the most external protein on the spore 
surface, BclA is likely to interact with the host environment.  
Recent discoveries from our group indicate for the first time 
that spores of B. anthracis are not merely passive targets of the 
complement system. We have previously reported that BclA of B. 
anthracis can bind to the classical complement pathway recognition 
protein C1q [29, 35]. These findings indicated that spore 
interaction with C1q plays a central role in spore entry into both 
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  phagocytic and non-phagocytic host cells. For phagocytic cells, the 
interaction results in classical complement pathway activation and 
opsonophagocytosis of spores in an IgG-independent manner [35]. For 
non-phagocytic cells, we reported that C1q acts as a bridging 
molecule between spore surface protein BclA and integrin α2β1 to 
mediate spore uptake in a complement activation-independent manner 
[29]. Recruitment of other components of the complement system by 
spores is less clear. 
In this study, we investigated whether BclA directly interacts 
with complement regulator fH. We observed that the B. anthracis 
spore binds human and mouse fH via direct interaction with its 
exosporium protein BclA. Strains that expressed segments or full-
length BclA protein bound fH significantly better than a deletion 
mutant of BclA. Both the CTD and CLR domains of BclA were involved 
in binding to fH. Interestingly, we hypothesize that B. anthracis 
spores appear to have developed a mechanism to suppress complement 
activation, by directly binding fH. 
 
EXPERIMENTAL PROCEDURES 
Bacterial strains and spore preparation. B. anthracis Sterne 
strain 7702, its isogenic deletion mutant strain (ΔbclA), B. 
subtilis strains PY79 and 168 were provided by T.M. Koehler, UT 
Health, Houston, TX. Complemented B. anthracis strains with full-
length BclA (ΔbclA/BclAFL), the C-terminal domain (ΔbclA/BclACTD), 
and the collagen-like region domain (ΔbclA/BclACLR) were constructed 
by fusing the respective BclA segments to the BclA endogenous 
promoter and NTD and introducing the construct back into the ΔbclA 
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  background as previously described by Tan et al [23]. Briefly, the 
constructs were cloned into an E.coli-B. anthracis pUTE583 shuttle 
vector: the region containing the 5’ non-coding sequence of BclA (to 
enable expression from the endogenous BclA promoter and ribosome 
binding site), the NTD (amino acid residues 1 – 38 of BclA, which is 
responsible for anchoring the protein to the exosporium [23]), and 
DNA fragments encoding the relevant regions of BclA or full-length 
BclA. The constructs were then introduced into the ΔbclA strain 
background [23]. B. subtilis 168 strains expressing full-length BclA 
(pDG1662/BclAFL) or the C-terminal domain (pDG1662/BclACTD) were 
constructed by taking the respective BclA segments (except the NTD) 
and fusing it to the C-terminus of CgeA [outermost surface protein 
on B. subtilis [11]. The fusion fragments were then cloned into 
vector pDG1662, which allows the ectopic integration of the fusion 
construct(s) at the non-essential amyE locus in the chromosome of B. 
subtilis [102, 103]. Immunofluorescence staining and flow cytometry 
using anti-BclA antibodies were performed to observe and quantify 
the expression levels of BclA on the surface of spores and the 
percentages of spores expressing the BclA protein. Spores of the B. 
anthracis strains were prepared by growing cultures on Luria Broth 
(LB) agar plates for 4 – 6 days in a 37°C incubator. The bacteria 
were scraped from the plates, washed three times with sterile cold 
Phosphate Buffered Saline (PBS) and heated twice for 30 minutes 
(min) at 68°C.  B. subtilis spores were prepared by culturing in 
Difco sporulation (DSM) media for 5 – 7 days at 30°C. The spore 
suspensions were then filtered through a 3.0µM filter, counted, and 
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  stored at 4°C. Bacterial titers were determined by plating on LB agar 
plates and incubation overnight at 37°C.  
Serum, proteins, and antibodies. Normal Human Serum (NHS) was 
purchased from CompTech. Mouse serum (MS) was obtained by terminal 
blood collection from the posterior vena cava of the mice. Blood 
samples were allowed to clot for 2 hours (hrs) at room temperature 
(RT) and then centrifuged for 15 min. Sera was collected and stored 
immediately at -80°C until used. Heat-inactivated serum was prepared 
by heating NHS or MS at 56°C for 30 min. Purified human fH was 
purchased from CompTech. Mouse bronchoalveolar fluid (BAL) was 
obtained by making a small incision in the mouse trachea to allow 
the passage of a 23-gauge lavage tube into the trachea. Mice lungs 
were lavaged thrice using cold PBS. A pooled sample of BAL fluid was 
collected and concentrated. Heat-inactivated BAL was prepared by 
heating at 56°C for 30 min. Goat anti-human fH antibodies were 
purchased from CompTech. Sheep anti-human fH antibodies were 
purchased from Abcam. Secondary antibodies were purchased from 
Invitrogen. Purified human fH and C3b were also purchased from 
CompTech. Heparin (5000 IU/ml) was purchased from Baxter Health Care 
Corporation. Expression and purification of BclA was done as 
previously described [29] with slight modifications. Briefly, full-
length and C-terminal domain BclA protein with an N-terminal His tag 
was expressed in Escherichia coli BL21 Rosetta 2 strain (Novagen). 
The recombinant protein was purified using Ni2+ affinity 
chromatography and ion-exchange chromatography in an AKTA prime plus 
FPLC system (GE Healthcare). The purified protein was analyzed by 
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  SDS-PAGE and Circular dichroism to evaluate the purity and the 
proper folding of the recombinant protein.  
Factor H binding to spores – Western blot analysis. 
Approximately 5 x 107 spores were incubated with 10µg/ml purified 
human fH, 10% heated NHS, 10% heated MS, or 100µl concentrated 
heated mouse BAL in the presence of 2.5mM D-alanine in PBS Buffer 
for 30 min at 37°C. Pellets were washed with cold PBS thrice. Equal 
amounts of spores were loaded onto a 12% SDS-PAGE and transferred to 
a nitrocellulose membrane for 50 min at 15V. The membrane was 
blocked with 5% milk in Tris-Buffered Saline with 0.05% Tween 20 
(TBST) for 1 hr and then incubated with goat anti-human fH or sheep 
anti-human fH (1:1000 for each) in TBST overnight at 4°C. Membranes 
were thoroughly washed and incubated with rabbit anti-goat HRP or 
rabbit anti-sheep HRP-conjugated IgG (1:000 for each) for 1 hr.  
Factor H binding to spores and recombinant proteins – Plate  
assay. Microtiter 2HB plates (Thermo Scientific) were coated with 
10µg/ml purified human fH in Hepes-Buffered Saline (HBS) overnight 
at 4°C. Wells were washed to remove unbound protein with HBS with 
0.05% Tween 20 (HBST) then blocked with 1% ovalbumin in HBST for 1 
hr at RT. Control wells were blocked with block buffer only. Biotin-
labeled spores with 2.5mM D-alanine were incubated at various 
dilutions for 30 min at 37°C followed by incubation with 
streptavidin-conjugated HRP (1:1000) for 1 hr. His-tagged 
recombinant proteins (rBclAFL and rBclACTD) were incubated with 
increasing concentrations of protein in blocking buffer at RT for 2 
hrs followed by incubation with anti-his HRP (1:3000) for 1 hr.  
Plates were developed with SigmaFast OPD and read at 450nm. 
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  Absorbance values were indicative of fH, with values from wells not 
incubated with spores or recombinant proteins subtracted as 
background.  
Factor H binding to spores – Flow Cytometry. Approximately 5 x 
107 spores were incubated with purified human fH (25µg/ml) in the 
presence of 2.5mM D-alanine for 30 min at 37°C.  Samples were washed 
with sterile saline and fixed with 2% paraformaldehyde (MeOH free) 
for 20 min at RT. Spores were labeled with goat anti-human fH 
(1:400) in PBS with 2% BSA for 1 hr at RT followed by donkey anti-
goat PE (1:400) in PBS with 2% BSA for another hr. Samples were 
analyzed with a flow cytometer (Accuri) using forward and side 
scatter parameters to gate on at least 20,000 spores. Results were 
compared using the mean fluorescence intensity (MFI).  
Effect of Heparin, C3b, and NaCl on BclA-Factor H binding. 
Purified human fH or ovalbumin (10µg/ml) was adsorbed to microtiter 
plates and incubated with a fixed concentration of rBclA [2µM] with 
the addition of heparin (10 to 1000 IU/ml), C3b (5 to 50µg/ml), or 
NaCl (10 to 300mM) for 2 hrs at RT. After incubation, wells were 
washed thrice with HBST and incubated with HRP-conjugated anti-his 
antibodies (1:3000). Absorbance was measured at 450nm. Experiments 
were repeated at least three times in duplicates.  
Statistical analysis. Statistical analysis was performed using 
the two-tailed Student’s t-test (Graph-Pad Prism 4.0).  
 
RESULTS 
 Factor H binds to the surface of B. anthracis spores. In order 
to analyze binding of host complement regulator fH to spores, the 
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  Sterne strain 7702 (pXO1+, pXO2-) and non-pathogencic B. subtilis 
PY79 strain were incubated in heat-inactivated normal human serum 
(HiNHS). After extensive washing, cell lysates were separated by 
SDS-PAGE, transferred to a membrane, and analyzed by Western blot 
analysis using anti-human fH antibodies. One distinct band of 
~150kDa was identified with 7702 spores, but was very weak with PY79 
spores. A representative Western blot is shown in Fig. 14, A. 
Furthermore, we assessed the direct binding of fH to B. anthracis 
spores by incubating the spores with purified human fH.  A similar 
band was detected for 7702 spores as with serum and a weaker band 
again was observed for PY79 spores (Fig 14, A). 7702 spores also 
showed binding to mouse fH when incubated with heated mouse serum 
(HiMS) or mouse bronchoalveolar lavage fluid (BAL) (Fig 14, A). B. 
subtilis spores weakly bound to mouse fH as seen with human fH. To 
further substantiate that B. anthracis spores bind fH directly, 
purified fH protein was adsorbed to the wells of a microtiter plate 
and incubated with various concentrations of 7702 or PY79 spores in 
an ELISA-type assay. 7702 spores bound fH in a dose-dependent 
manner, with >100-fold better binding than PY79 spores (Fig. 14, B). 
Additionally, flow cytometry analysis utilizing purified human fH 
indicated that 7702 spores significantly bound fH better than PY79 
spores (Fig. 14, C). These results support that a dose-response 
relationship exists for fH binding to B. anthracis spores. Also, 
spores of B. subtilis had minimal binding to fH, suggesting that 
spores of B. anthracis possess a fH bacterial ligand on its spore 
surface that is either absent or distinct from that of B. subtilis 
spores.  
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   Factor H binds to spore surface protein BclA. In order to 
characterize the bacterial ligand mediating this interaction, we 
hypothesized that the B. anthracis BclA protein might represent the 
binding protein. BclA is the major surface protein and 
immunodominant antigen on B. anthracis spores [12]. Therefore, it is 
a likely target to interact with host complement proteins. To assess 
if BclA is important in fH binding, we utilized the B. anthracis 
BclA deletion mutant (ΔbclA) and compared binding of fH to our 
parent strain (7702). Spores were incubated in HiNHS, HiMS, mouse 
BAL, and purified human fH as indicated above. Mutant bclA spores 
revealed a weak band around 150kDa similar to B. subtilis PY79 
spores (Fig. 14, A). Only 7702 spores revealed a strong band for fH. 
Additionally, we performed an ELISA-type assay and flow cytometry 
analysis using purified human fH to confirm that BclA is important 
for fH recruitment on spores. The results indicate that 7702 spores 
bound >10-fold better to fH than the deletion mutant on microtiter 
plates and significantly better in solution (Fig. 14, B and C).  
  We next complemented the BclA deletion mutant with full-length 
BclA (ΔbclA/BclAFL) as described in experimental procedures to 
investigate if the presence of BclA can increase the ability of 
ΔbclA spores to bind to fH. To verify BclA on the surface of spores 
we stained the spores with anti-BclA antibodies. Complemented spores 
stained positive for BclA protein similar to 7702 spores, but ΔbclA 
spores did not (Fig. 15, A – C). We also measured the expression 
levels of BclA on the surface of spores and quantitated the 
percentage of spores expressing BclA in our spore preparations by 
flow cytometry analysis (Fig. 16). Both 7702 and ΔbclA/BclAFL spores 
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  had significantly higher BclA expression than ΔbclA spores (Fig. 16, 
D). In fact, ΔbclA/BclAFL spores had higher expression than 7702 
spores suggesting that the complemented strain expressed greater 
levels of BclA protein on its surface. Approximately >65% of 7702 
spore preparations expressed BclA protein on their surface and about 
>80% of the complemented strain preparations (Fig. 16, E). As 
expected, the deletion mutant did not express BclA protein on its 
surface. We then tested the ΔbclA/BclAFL spores in binding to fH. We 
used the previously described combination of Western blot, ELISA, 
and flow cytometry approaches to compare the binding of fH with 
these different spores. As shown in Fig. 17, ΔbclA/BclAFL spores had 
significantly greater fH binding with at least a 3-fold difference 
than the deletion mutant (Fig. 17, B and C). These results show that 
B. anthracis spores require BclA protein to bind to fH.  
 B. subtilis expressing BclA bound factor H. To further examine 
the fH binding ability of BclA, we used B. subtilis spores 
expressing BclA. The B. subtilis genome does not encode BclA nor do 
these spores contain an exosporium [83]. We have also shown that 
spores of B. subtilis PY79 do not show direct binding to fH. Thus, 
B. subtilis spores can be used as a heterologous host to display 
BclA protein. Full-length BclA protein was expressed on the surface 
of B. subtilis spores as described in the experimental procedures. 
We performed immunofluorescence staining and flow cytometry with 
anti-BclA antibodies to verify BclA expression on the surface of 
these spores (Fig. 18, A – E). B. subtilis (pDG1662/BclAFL) was 
compared to the empty vector control B. subtilis (pDG1662) spores. 
B. subtilis spores expressing BclA (pDG1662/BclAFL) stained positive  
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  for BclA protein and had significantly greater BclA expression 
compared to the empty vector pDG1662 (Fig. 18, F). Approximately 
>90% of pDG1662/BclAFL spores expressed BclA protein while there was 
no BclA protein detected for pDG1662 spores (Fig. 18, G). In fH 
binding assays, pDG1662/BclAFL spores bound 8-fold more fH than 
pDG1662 spores and the difference observed was significant (Fig. 19, 
A and B). Additionally, a fH band was detected with pDG1662/BclAFL 
spores compared to the pDG1662 spores in Western blot analysis (Fig. 
19, C), confirming that the surface expression of BclA enhanced the 
binding of fH to B. subtilis.  
 Recombinant BclA binds purified factor H in a dose-dependent 
manner. To investigate the fH-binding ability of B. anthracis, we 
used the recombinant form of the BclA protein. Full-length BclA 
protein (BclAFL) was expressed and purified as a his-tagged 
recombinant protein. The recombinant protein formed a triple helix 
as shown by Circular dichroism (CD) spectra of a positive 
ellipticity at 220nm typical of a triple helix formation [26] (Fig. 
20, A). Also, the recombinant protein was monitored by CD at 220nm 
from 6 – 50°C. Recombinant BclA protein had a melting temperature 
around 35°C and the helix was completely denatured at >40°C (Fig. 20, 
B). On an SDS-PAGE under reducing conditions rBclAFL migrated at 
about 70kDa and under non-reducing conditions migrated as an SDS-
resistant trimer (>180kDa) as previously described [26] (Fig. 20, 
C). To verify the protein observed in the Coomassie stain was indeed 
our protein, we performed a Western blot using anti-his antibodies 
and detected a band at similar molecular weights as seen on the 
Coomassie stain (Fig. 20, D). To examine fH binding with rBclAFL,  
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  purified human fH or control protein ovalbumin was adsorbed to 
microtiter plates and incubated with increasing concentrations of 
rBclAFL in an ELISA-type assay. As shown in Fig. 21, rBclAFL bound 
to fH in a dose-dependent and saturable manner, with a KD of ~0.9 ± 
0.45µM, which is >1000 fold more than ovalbumin. These results 
strongly suggest that BclA is indeed a fH binding protein of B. 
anthracis.  
 Mapping of BclA-Factor H binding domain. Recombinant protein 
and engineered spores expressing different domains of BclA were used 
to determine which region of BclA was responsible for the 
interaction with fH. First, we cloned the C-terminal domain of BclA  
(BclACTD) into the pBAD expression vector to generate a his-tag 
fusion protein and we purified the protein as described in 
experimental procedures. Analysis of the recombinant protein in CD 
spectra revealed an all beta structure similar to previous reports 
of its crystal structure [85] (Fig. 22, A). On a Coomassie stain 
rBclACTD migrated at about 17kDa and formed trimers under non-
reducing conditions (~>40kDa; Fig. 22, B). Western blot analysis 
revealed a band at a similar molecular weight as seen in the 
Coomassie stain (Fig. 22, B). ELISA results showed that rBclACTD 
mediated binding to fH similar to rBclAFL (Apparent KD for rBclAFL = 
0.9 ± 0.45µM and rBclACTD = 2.1 ± 0.80µM, Fig. 23). To further assess 
the involvement of CTD in mediating binding to fH, B. subtilis 
spores were engineered to express the C-terminal domain of BclA. 
Expression of BclA on the surface of spores was again verified by 
immunofluorescence staining and flow cytometry (Fig. 24). Spores 
expressing the C-terminal domain (pDG1662/BclACTD) had higher levels  
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  of BclA expression compared to pDG1662/BclAFL and pDG1662 spores 
(Fig. 24, C). The percentage of spores expressing BclA was similar 
between pDG1662/BclAFL and pDG1662/BclACTD (Fig. 24, F). Western 
blot assays showed that pDG1662/BclACTD spores bound purified fH 
similar to pDG1662/BclAFL spores. A representative blot is shown in 
Fig. 25, A. ELISA and flow cytometry results indicated that 
pDG1662/BclACTD spores significantly bound to immobilized and 
soluble fH compared to pDG1662 spores (Fig. 25, B and C), suggesting 
that the CTD of BclA is involved in the interaction with fH. We were 
unsuccessful in generating a recombinant protein of the collagen-
like region of BclA and engineering B. subtilis spores to express 
this specific region (BclACLR). However, we were able to complement 
B. anthracis ΔbclA spores with both the CTD and CLR regions of BclA. 
These spores were verified for BclA expression using anti-BclA 
antibodies as shown in Fig. 26, B and C. ΔbclA/BclACLR and 
ΔbclA/BclACTD spores had similar BclA expression levels compared to 
7702 spores, but were lower than ΔbclA/BclAFL (Fig. 26, F). Also, 
the percentages of spores expressing BclA in different spore 
preparations were not significantly different among the different 
BclA-expressing spores (≥50% of spores expressed BclA; Fig. 26, G). 
We next examined fH binding with these complemented spore strains 
(ΔbclA/BclACLR and ΔbclA/BclACTD). Spores were incubated with 
purified human fH or HiNHS, washed, and cell lysates were prepared. 
ΔbclA/BclACLR and ΔbclA/BclACTD spores were able to bind to purified 
fH and serum fH (data not shown) as determined via Western blot. A 
representative Western blot is shown in Fig. 27, A. The band 
detected for the complemented fragment domains were stronger than 
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  the band detected for 7702 and ΔbclA/BclAFL spores. A very weak band 
was detected for the deletion mutant (ΔbclA). Flow cytometry results 
indicated that ΔbclA/BclACLR and ΔbclA/BclACTD bound fH similarly 
and better than ΔbclA/BclAFL. These results suggest that both the 
CTD and CLR domains of BclA are involved in the ability of BclA to 
bind to fH.  
 Characteristics of BclA-Factor H interaction. Many other 
bacterial fH binding proteins (e.g. M6 protein of S. pyogenes [47], 
Ali of Y. enterocolitica [94], and OMPs of H. influenza [104]) have 
been reported to bind fH in the same regions in fH that have been 
described to bind host cell markers such as heparin. In order to 
deduce which site on fH is responsible for BclA binding, we first 
examined whether BclA binds to the heparin binding sites on fH (i.e. 
SCRs 7, 13, and 19 – 20) [44]. Using ELISA-type assays, purified 
human fH was adsorbed to microtiter plates and incubated with a 
fixed concentration of rBclA with or without increasing 
concentrations of heparin (10 – 1000IU/ml). Even at the highest 
concentration of heparin tested, rBclA binds to fH similar to when 
no heparin is present (Fig. 28, A). These results suggest that the 
binding site on fH for BclA does not involve the heparin binding 
sites.  
C3b is also another important ligand for fH and the interaction 
is pivotal for fH complement regulation and host surface 
recognition. We next investigated whether BclA interacted on C3b 
binding sites (SCRs 1 – 4, 6 – 8, 12 – 14, and 19 – 20) [44]. ELISA 
results indicated that a range of 5 – 50µg/ml of C3b did not 
interfere with rBclA binding to fH adsorbed on microtiter plates  
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  (Fig. 28, B). Like heparin, C3b binding sites on fH at these 
concentrations do not seem to overlap with BclA binding sites on fH.  
Lastly, fH recognition of polyanions as well as other fH 
ligands suggests that ionic interactions may be important for 
binding. We determined if BclA-bound fH was affected by different 
salt concentrations. To investigate this we tested if binding 
between fH and rBclA would be different if the salt concentrations 
in the buffer were increased from 10 to 300mM (Fig. 28, C and D). 
Our results showed that better binding between fH and rBclA occurred 
at concentrations >50mM. Additionally, we have shown throughout our 
experimental assays with spores that our buffers contain 
physiological concentrations of salt (150mM NaCl) and are able to 
interact specifically with fH. This data supports that ionic 
interactions may not be important for BclA binding to fH and that it 
is likely that BclA-fH interaction occurs in vivo.  
 
DISCUSSION 
 Many pathogenic bacteria express proteins that interfere with 
the host defense mechanism, with complement evasion as a central 
strategy to their success in causing infection, survival, 
persistence, and disease in a host. As a highly successful pathogen, 
B. anthracis is no exception. B. anthracis spores are known to 
persist for long periods of time in infected hosts [7-9]. It is thus 
intriguing how spores overcome the host immune defenses. Our current 
knowledge of the ability of B. anthracis to subvert the complement 
system is limited and in the present study, we report that B. 
anthracis spores can recruit complement regulator protein fH to its 
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  spore’s surface, and this is specifically mediated by BclA. BclA is 
the outermost surface protein of B. anthracis spores, comprising the 
hair-like nap. It is known to mediate entry into phagocytes [27, 28] 
and non-phagocytic cells [29]. The first demonstration that BclA 
interacts with complement proteins was described by Gu et al in 2012 
[35].  
 We identified BclA as a fH-binding protein using several 
techniques including Western blot, ELISA, and flow cytometry to 
provide insights into the interaction between fH and B. anthracis 
spores. We presented data showing enhanced binding of fH to 7702 
spores compared to spores from a BclA deletion mutant and a non-
pathogenic B. subtilis strain, which lacks the gene that encodes for 
BclA. Deletion of BclA significantly reduced binding to fH, but did 
not abolish it. We cannot rule out the possibility that other 
proteins exposed when BclA is not present can mediate fH binding on 
these spores. Also, it has been reported that ΔbclA spores bind more 
readily than the parental strain spores to extracellular matrix 
proteins, fibronectin and laminin [105], suggesting that other 
proteins on ΔbclA spores may play a role in B. anthracis immune 
evasion. However, additional experiments showed that complementation 
of the isogenic BclA mutant strain increased its ability to bind to 
fH, indicating that BclA is the major fH-binding protein on the 
surface of B. anthracis spores. Studies using the recombinantly 
expressed BclA validated the ability of this protein to bind to fH 
whether purified or in serum, with a dose-dependent relationship 
evident. The relative affinity of rBclA for fH appears to be in the 
similar range (0.59 – 2.9µM) as the affinity reported for fH 
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  interaction with C3 fragments [38]. Also, the buffer used in the 
experimental assays contained physiological concentrations of salt 
(~150mM NaCl). This indicates that the interaction between BclA-fH 
is likely to occur in vivo. Furthermore, displaying heterologous 
proteins on the surface of B. subtilis spores has been used in many 
studies [106-111]. The principal approach used here was to fuse BclA 
protein to CgeA, a protein in the B. subtilis spore crust. The spore 
crust has been recently discovered as the outermost structure on the 
surface of B. subtilis spores [11]. Using a heterologous host, B. 
subtilis, we demonstrated that BclA expression on a bacterial 
surface significantly enhanced fH recruitment, which confirms our 
rBclAFL-fH binding data.  
  Moreover, we sought to determine the extent to which 
complement activation affects the binding of fH to B. anthracis. In 
heat-inactivated serum, which complement proteins become inactive 
and fH remains heat-stable, fH bound B. anthracis spores 
demonstrating that complement activation is not necessary for fH 
binding. This has also been reported for S. aureus strains [112]. In 
addition, our Western blot analysis suggest that B. anthracis may 
also bind to FHL-1 or fH-related proteins (data not shown), since we 
did observe faint bands at the respective molecular weights (~36 – 
43kDa). Other pathogenic bacteria such as S. pyogenes [113], S. 
auerus [112], and B. burgdorferi [114] have also been shown to 
interact with these proteins.   
 We further examined which region of BclA was responsible for 
the interaction with fH. From our studies, we report that both the 
CTD and CLR domains of BclA can bind to fH. Interestingly, from flow 
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  cytometry analysis we see that spores expressing CLR or CTD bind 
similar to fH suggesting that there may be two binding sites located 
on BclA for fH. Further clarification of the binding regions on BclA 
for fH binding will be determined in future experiments. Our results 
also provide insight into the regions on fH that are important for 
binding. The majority of fH binding proteins have been described to 
bind to domains 19 – 20 on fH [37]. A few have been described for 
interaction on heparin (SCR7) and C3b (6 – 8 and 19 – 20) binding 
sites, including M proteins and Fba of S. pyogenes, PorB 1A of N. 
gonorrhoeae, Ail of Y. enterocolitica, Tuf of P. aeruginosa, and Sbi 
of S. aureus [37]. For B. anthracis, our results indicate that BclA 
protein does not interact on heparin or C3b binding sites, 
suggesting that SCR domains (1 – 4, 6 – 8, 12 – 14, and 19 – 20) may 
not be involved in this binding interaction. Available sites that 
were not tested for BclA-fH binding include SCRs (5, 9 – 11, and 15 
– 18). CRASP 1 protein of Borrelia species is known to interact at 
SCR 5 [115]. PspC protein of S. pneumonia has been described to 
interact at SCR 9 – 11 and 15 [52, 53]. No fH binding proteins have 
been described to interact at SCRs 16 – 18. However, it is possible 
that BclA may interact with the entire molecule of fH similar to 
what has been described for the fH binding protein of Y. 
enterocolitica (Yad A) [94, 116].  Future investigations for the fH 
binding regions will better clarify these conclusions.  
In summary, the interaction between B. anthracis and complement 
proteins is only beginning to be explored. Our data clearly 
demonstrate that B. anthracis binds fH in a dose-dependent manner 
requiring neither complement activation, nor C3b or other serum 
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  components. BclA is the major fH-binding molecule on the spore 
surface due to its ability to bind fH whether purified or in serum. 
To our knowledge, this is the first description of a B. anthracis 
spore surface protein that recruits a complement regulator. Future 
studies will address whether fH binding to spores via BclA 
suppresses complement activation on the spore surface and will 
survey the biological role of BclA-fH interaction in the development 
and chronic stages of anthrax infections. 
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  Chapter 4: BIOLOGICAL FUNCTION OF BCLA-FACTOR H INTERACTION 
 
INTRODUCTION 
 Our results in Chapter 3 suggest that B. anthracis spores have 
evolved a sophisticated mechanism to interact with the complement 
regulator protein fH via the spore surface protein BclA. Because fH 
is a major immune suppressor of complement, we wanted to know if the 
fH-BclA interaction could be an immune suppression mechanism 
important for spore persistence in a host (introduced and studied in 
Chapter 2). Spore persistence in the lungs of animals has been well 
known for many decades [7-9]; however the mechanisms that contribute 
to spore persistence is unclear. Our studies described in Chapter 2, 
demonstrated that anthrax toxins, in particular lethal factor, a 
major immune suppressor of B. anthracis, do not play a role in spore 
persistence in the lung. Also, one of the general theories regarding 
spore persistence is that spores are able to persist due to their 
dormant and resilient properties. Therefore, the host does not 
efficiently kill them. It is also possible that the lung is able to 
tolerate spores in general. However, we found that spores of B. 
subtilis did not persist in the lung as well as those of B. 
anthracis, suggesting that B. anthracis spores possess special 
properties that promote their survival and persistence in the lung. 
The exosporium is the outermost integument of B. anthracis spores, 
but is not present on B. subtilis [83]. The exosporium is composed 
of 20 – 30 proteins and glycoproteins [83]. It is possible that 
specific exosporium components may have immune suppression 
properties. Results described in Chapter 3 suggest that direct 
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  interactions with complement inhibitor fH by B. anthracis spores via 
the exosporium protein BclA may play a role in mediating persistence 
in a host.  
 In this study, we sought to determine the biological function 
of B. anthracis spore interaction with fH. FH is abundantly present 
in plasma and is therefore a prime target for sequestration by 
pathogens where surface-bound fH can benefit their survival in a 
host. We used the spore persistence model that we previously 
developed (described in Chapter 2) to first evaluate the role BclA 
protein plays in spore persistence in the lungs of mice. And then to 
evaluate the role of binding of fH by challenging mice with spores 
that either were capable or incapable of binding to fH in our 
binding assays. To determine the significance of fH recruitment by 
BclA, we examined whether BclA-bound fH remained functionally active 
and able to act as a cofactor for factor I-mediated cleavage of C3b. 
We then determined whether the conversion of C3b to iC3b on the 
surface of spores occurs. We expected to find that fH binding leads 
to less complement activation on the spore surface and that there is 
a positive correlation between fH-binding and spore survival in 
persistent infections.  
 
EXPERIMENTAL PROCEDURES 
Bacterial strains and spore preparation. B. anthracis Sterne 
strain 7702, its isogenic deletion mutant strain (ΔbclA), and B. 
subtilis strains 168 were provided by T.M. Koehler, UT Health, 
Houston, TX. Complemented B. anthracis strains with full-length BclA 
(ΔbclA/BclAFL), the C-terminal domain (ΔbclA/BclACTD), and the 
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  collagen-like region domain (ΔbclA/BclACLR) were constructed by 
fusing the respective BclA segments to the BclA promoter. The 
constructs were cloned into an E.coli-B. anthracis pUTE583 shuttle 
vector. The construct was then introduced into the ΔbclA strain 
background. B. subtilis 168 strain expressing full-length BclA 
(pDG1662/BclAFL) or the C-terminal domain (pDG1662/BclACTD) was 
constructed by taking the respective BclA segments (except the NTD) 
and fusing it to the C-term of CgeA. The fusion fragments were then 
cloned into vector pDG1662 and integrated into the B. subtilis 168 
strain chromosome at the amyE locus. Immunofluorescence staining and 
flow cytometry using anti-BclA antibodies were performed to observe 
and quantify the expression levels of BclA on the surface of spores 
and the percentages of spores expressing BclA protein for each spore 
preparation. Spores of the different B. anthracis strains were 
prepared by growing cultures on Luria Broth (LB) agar plates for 6 – 
8 days in a 37°C incubator. The bacteria were scraped from the 
plates, washed three times with cold sterile Phosphate Buffered 
Saline (PBS) and heated twice for 30 minutes (min) at 68°C. B. 
subtilis spores were prepared by culturing in Difco sporulation 
(DSM) media for 5 – 7 days at 30°C, washed with cold sterile PBS and 
heated twice for 30 min at 68°C.  The suspension was then filtered 
through a 3.0µM filter, counted, and stored at 4°C. Bacterial titers 
were determined by plating on LB agar plates and incubation 
overnight at 37°C. 
Mouse Infections. All animal experiments were carried out 
according to procedures approved by the Institutional Animal Care 
and Use Committee, Texas A&M Health Science Center, Institute of 
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  Biosciences and Technology. BALB/c and C57Bl/6 mice were originally 
purchased from the Jackson Laboratory. C1q-/- mice [117] were 
obtained from Dr. Marina Botto, Imperial College London, UK. All 
mice were maintained in the IBT animal facility. For infection 
experiments, 6 – 8 week old and sex-matched mice were used. Mice 
were inoculated with spores by intranasal instillation (i.n.) as 
previously described [29]. Briefly, mice were anesthetized with 
avertin (0.3mg/g) by intraperitoneal injection (i.p.). Mice were 
then inoculated i.n. with 20µls of a sub-lethal dose of spores (1.5 
x 107 spores). Mice were monitored twice daily over a two-week 
experimental period. Mice mostly appeared healthy with no physical 
signs of distress or illness throughout the experiments. 
Occasionally a few mice died within the experimental period and were 
not included in the data analysis. To determine the bacterial burden 
in the lungs, mice were euthanized by i.p. injection of avertin 
followed by exsanguination via the inferior vena cava. Lungs were 
collected at two weeks post-infection. The tissues were homogenized 
in sterile cold PBS plus D-alanine, pH 7.4 (1ml final volume) using 
a tissue homogenizer (Fisher Scientific). The lung homogenates were 
either directly diluted and plated to determine the number of total 
viable bacteria or heated at 68°C for 30 min and dilution plated in 
serial dilutions to determine the number of heat-resistant spores.  
Deposition of iC3b on spores – Flow cytometry. Approximately 5 
x 107 spores were incubated with 10% Normal Human Serum (NHS, 
CompTech) in the presence of 2.5mM D-alanine for various time points 
at 37°C.  Samples were thoroughly washed with sterile saline and then 
fixed with 2% paraformaldehyde (MeOH free) for 20 min at room 
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  temperature (RT). Spores were labeled with mouse anti-human iC3b 
(1:400; Quidel) in PBS with 2% BSA for 1 hour (hr) at RT followed by 
donkey anti-mouse 647 (1:400; SantaCruz) in PBS with 2% BSA for 
another hr. Samples were analyzed with a flow cytometer (Accuri) 
using forward and side scatter parameters to gate on at least 20,000 
spores. Results were compared using the value for the mean 
fluorescence intensity (MFI).  
Statistical analysis. Statistical analysis was performed using 
the two-tailed Student’s t-test (Graph-Pad Prism 4.0).  
 
RESULTS 
BclA is an important factor for spore persistence in mice. To 
evaluate if BclA plays a role in B. anthracis spore persistence, 
BALB/c mice were challenged intranasally (i.n.) with 1.5 x 107 spores 
of B. anthracis Sterne Strain 7702 or its isogenic BclA deletion 
mutant (ΔbclA). The presence of vegetative bacilli and spores in the 
lungs was evaluated over a period of 2 weeks. The results indicated 
that significantly greater numbers of bacteria were recovered from 
mice infected with 7702 spores compared to mice infected with ΔbclA 
spores (Fig. 29, A). On average 7.8 x 105 ± 1.7 x 105 and 5.8 x 104 ± 
2.5 x 104 colony forming units (cfu) were recovered from the mice 
infected with 7702 and ΔbclA spores, respectively. The majority of 
the bacteria (79%) recovered were heat resistant dormant spores 
similar to what was reported in our results in Chapter 2. To further 
evaluate BclA as an important factor in spore persistence, mice were 
challenged with the complemented strain ΔbclA/BclAFL.  The number of 
bacteria recovered from the lungs of mice infected with ΔbclA/BclAFL  
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  was significantly greater than the number recovered from mice 
infected with ΔbclA (Fig. 29, B). These results suggest that the 
presence of BclA on the surface of B. anthracis spores is likely to 
contribute to their ability to survive and reside in the infected 
host for long periods of time.  
We next determined if specific regions of BclA known to be 
important for fH-binding persisted in our mice model. BALB/c mice 
were infected i.n. with a sub-lethal dose (1.5 x 107 spores) of 
ΔbclA/BclACLR or ΔbclA/BclACTD spores. We observed that 
complementation with the CLR region of BclA resulted in a similar 
number of bacteria recovered in the lung as mice infected with 
BclAFL (Fig. 29, B). The number of spores recovered was 
significantly greater than the parental strain (ΔbclA). A different 
result was found with the complementation of the CTD region. Mice 
infected with ΔbclA/BclACTD had a slightly higher bacterial load in 
their lungs compared to mice infected with ΔbclA spores (7.8 x 104 ± 
2.9 x 104 vs. 5.8 x 104 ± 2.5 x 104 cfu) but lower than those infected 
with ΔbclA/BclACLR. We also challenged mice with B. subtilis spores 
expressing BclAFL and BclACTD. We observed that mice infected with 
both BclAFL and BclACTD spores had significantly greater numbers of 
cfu recovered from their lungs compared to mice infected with 
pDG1662 spores (Fig. 30). Collectively, the data indicate that 
spores that express BclA are better at persisting in the lung than 
spores that do not express BclA. Also, strains that have the ability 
to bind to fH (7702, ΔbclA/BclAFL, ΔbclA/BclACLR, ΔbclA/BclACTD, 
pDG1662/BclAFL, and pDG1662/BclACTD) are more likely to persist in 
the host than strains that do not (ΔbclA and pDG1662).  
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Spore persistence does not involve C1q.  C1q is the ligand 
recognition subunit of the C1 complex of the classical complement 
pathway. It is able to interact with a variety of ligands, and 
functions in both a complement activation-dependent and –independent 
manner [118, 119]. We have shown that spores can initiate the 
classical complement pathway via a direct interaction between BclA 
and C1q [35] and we have demonstrated that C1q mediates spore entry 
into host epithelial cells using BclA and integrin α2β1 [29]. With 
respect to the direct interaction between B. anthracis spores and 
fH, we wanted to examine if the differences we saw in the 
persistence experiments described above were due to the ability of 
BclA binding to C1q. Therefore, we compared the lung cfu between 
wild-type (WT; C57Bl/6) and C1q-/- mice using all spore strains 
described above. The results demonstrated there was no detectable 
differences in the number of spores recovered from WT versus C1q-/- 
mice for any strain tested, indicating that C1q is not involved in 
spore persistence in a host (Fig. 31). This data further supports 
the theory that the fH-binding function of BclA is likely important 
for spore persistence.  
BclA suppresses complement activation on the spore surface. FH 
negatively affects the formation of complement activating complexes 
(i.e. C3 convertase) and therefore is known to dampen the host 
immune response. We sought to examine the extent to which the 
surface expression of BclA affected the rate of iC3b conversion on 
the B. anthracis spore surface in order to determine whether BclA-
bound fH is functionally active in its ability to provide cofactor  
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  activity for factor I-mediated cleavage of C3b. 7702 and ΔbclA 
variants were incubated with NHS to allow complement activation via 
all pathways. The reactions were stopped at various time points, 
washed, and subjected to flow cytometry analysis using iC3b-specific 
antibodies. Over time, BclA-expressing strains had more iC3b 
deposited on the surface of their spores compared to the BclA 
deletion mutant (Fig. 32, A). We also performed a linear regression 
to calculate the slope, which represented the rate of iC3b over 
time. Similarly, BclA-expressing strains were faster at converting 
C3b to iC3b on their surfaces than the deletion mutant (Fig. 32, B). 
This data suggests that BclA is important for the conversion of C3b 
to iC3b on the surface of spores and this activity possibly involves 
its interaction with fH.   
 
DISCUSSION 
 The most severe anthrax infections in humans occur via the 
inhalation of B. anthracis spores. Even with antibiotic treatment, 
inhalational anthrax is associated with high mortality and 
morbidity. A key feature of this form of anthrax is the persistence 
of spores in the lung of infected hosts for long periods of time. 
This is the basis for the prolonged antibiotic regimen (60 days) 
recommended for infected individuals. However, an underlying 
mechanism for spore persistence remained unknown. In Chapter 2, our 
results suggested that spore persistence is more than simply due to 
the dormancy of spores or hiding in a particular intracellular 
niche, rather there may be a general mechanism for avoiding and 
suppressing host immune recognition and clearance. The complement  
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  system is an important effector mechanism for host defense against 
microbial pathogens. There are several mechanisms that pathogens can 
use to circumvent innate immune killing through the complement 
system. Most commonly reported in the literature include the 
production of capsule to prevent complement recognition and the 
secretion of molecules that inactivate complement proteins. For 
example, the Staphylococcal complement inhibitor (SCIN) protein of 
S. aureus is a highly effective C3 convertase inhibitor that blocks 
conversion of C3 [120]. Another example is the cysteine protease 
SpeB of S. pyogenes that cleaves C3 and degrades C3b, thus escaping 
phagocytosis [121]. Alternatively, pathogens can recruit host 
complement regulators to their bacterial surface. We provided 
evidence in Chapter 3 that B. anthracis can bind fH and this 
interaction requires the spore surface protein BclA. Although fH has 
been shown by numerous other pathogens to subvert the complement 
system, this is the first report demonstrating its protective 
activity in B. anthracis spore survival in the host.  
We first investigated whether the spore surface protein BclA 
was important for spore persistence. We previously determined a 
potential niche of spore persistence in the lung where primarily 
dormant spores were found to be closely associated with the lung 
epithelium for at least 8 weeks. Spore survival within the lung was 
much greater than those in other tissues indicating a potentially 
special circumstance of pathogen immune evasion and/or tissue 
tropism. It is likely that spore persistence in the lung is 
responsible for the ability of B. anthracis to cause disease 
recurrence. BclA, the outermost and very abundant protein of the 
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  spore exosporium was a likely target to be involved in mediating 
spore persistence. We found that spores lacking BclA protein did not 
survive as well as spores that expressed full-length or fragments of 
BclA in mice. Among its other functions described for BclA (i.e. 
entry into host cells) this is the first demonstration that BclA on 
the surface of spores contributes to the persistence of spores in 
the host. To further evaluate the importance of BclA in this 
mechanism of persistence, we used a spore-forming heterologous host 
(B. subtilis) to display the same BclA variants on the spore 
surface. Our findings show that B. subtilis spores that expressed 
full-length BclA or fragments of BclA remained in the mouse lungs in 
greater numbers than spores that did not express BclA (pDG1662). 
Moreover, B. anthracis spores expressing the CTD of BclA were 
not significantly different from the parental strain (ΔbclA) with 
regards to persisting in the mouse lung. It is possible that the 
proper display of the CTD on the surface of B. anthracis contributes 
to this result even though the expression level of BclA is similar 
to that of 7702 spores. We did observe B. subtilis spores expressing 
the CTD of BclA persisting in the mouse lung, so we cannot exclude 
that the C-terminal region of BclA is important in this mechanism of 
persistence. Further studies utilizing transmission electron 
microscopy are needed to validate the proper display of BclA on the 
surface of B. subtilis and B. anthracis spores.  
FH deficient mice (Cfh-/-) are known to have uncontrolled C3 
activation resulting in C3 depletion from plasma. Therefore, Cfh-/- 
mice were not suitable for determining the role of fH during 
infections. To determine if B. anthracis-fH interaction is a 
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  mechanism for persistence, the role of fH recruitment by BclA was 
inferred by using engineered spores that bound or did not bind to 
fH. Our results indicated that strains that are fH binding (BclA-
expressing strains) were more likely to persist in the mouse lung 
than strains that did not express BclA (ΔbclA and pDG1662, non-fH 
binders). Determining the minimal binding region between BclA and fH 
and/or defining mutants that abolish fH binding would greatly 
strengthen the evidence for BclA-fH binding in vivo. Also, studies 
to determine the levels of intracellular/extracellular spores with 
the various BclA strains would provide clues on the survival 
potential of these spores within the lung. It would be interesting 
to see whether altering the surface display of the spores would 
change their specific location within the lung.  Moreover, C1q was 
shown to not be involved, providing further validation that fH 
contributes to the persistence phenomenon. C1q-/- mice had similar 
numbers of bacteria and spores in the lungs of mice compared to 
wild-type mice, which excludes the direct BclA-C1q interaction.  
With respect to the regulatory role of surface-attached fH, 
degradation of C3b was analyzed directly at the surface of B. 
anthracis spores after incubation with human serum. For all analyzed 
strains, iC3b deposition was more pronounced for strains that were 
BclA-expressing and had fH-binding activity. These specific spores 
were also faster at converting C3b to iC3b on the spore surface. 
Other bacterial fH-binding proteins (e.g. Yad A and Tuf) have been 
reported to promote factor I-mediated cleavage of C3b [94, 122]. Our 
unpublished data also reveals that iC3b coated spores survive better 
after phagocytosis than did non-coated spores (data not shown). 
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  Collectively, these results indicate that the BclA-fH interaction 
likely contributes to an immune evasion strategy for the persistence 
of spores in the host.  
Further insight into how BclA affects the longevity of B. 
anthracis spores in a host is that the presence or absence of BclA 
may affect the germination potential of spores and in turn affect 
their ability to survive in the lung. Brahmbhatt et al reported that 
the BclA deletion mutant germinated at a faster rate than the parent 
strain in vitro and in vivo, suggesting that BclA may slow spore 
germination in vivo [105]. Also, it has been known for many years 
that spores do not readily germinate in the alveolar spaces of the 
lung [123]. If this is true, then we would speculate that the slight 
delay in germination of B. anthracis spores may allow greater 
numbers of spores to survive (i.e. BclA is present longer, spores 
are able to recruit fH allowing for iC3b conversion to take place) 
and therefore spores are likely to remain longer in the host.    
In summary, here we describe an uninvestigated area in B. 
anthracis research; that is a mechanism for spore persistence. The 
data presented highlights that fH-binding by BclA is a mechanism to 
limit complement activation on the spore surface and consequently 
promotes spore survival and persistence in the lung. We were able to 
demonstrate that there is a positive correlation between fH-binding 
strains (BclA-expressing strains) and spore survival in persistent 
infections. Future experiments will further confirm these 
conclusions and determine the general role of fH-binding in anthrax 
infections.  
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  Chapter 5: DISCUSSION 
 
 More than a 100 years ago after its initial discovery to cause 
disease, Bacillus anthracis remains at the forefront of research 
because of its potential as a biological weapon. The significance of 
anthrax as a terror weapon was realized in 2001. Since then new 
research findings are improving our understanding of how B. 
anthracis causes disease and how to better prevent and treat it in 
case of a bioterrorism event.  
 One of the characteristic features of pulmonary anthrax is that 
spores could remain in the lungs for weeks, even months in infected 
animal hosts [7-9]. This retention of spores in vivo necessitated 
the prolonged use of prophylactic antibiotics for patients with 
pulmonary exposure to B. anthracis spores. The recommended 
antibiotic regimen is 60 days with an option for a 40-day additional 
treatment. However, the optimal duration of prophylaxis still 
remains unclear. Minimizing the duration of post-exposure antibiotic 
prophylaxis could be crucial to a successful defense against a 
large-scale bioterrorism attack. However, no investigations have 
been conducted to determine the characteristics and molecular 
mechanisms of spore persistence in an infected host, which is vital 
to understanding how to treat post-exposure prophylaxis.  
Here, we developed a persistence model of inhalational anthrax 
in mice. The impact of our findings to B. anthracis pathogenesis is 
highly significant. We report that there are multiple mechanisms 
that contribute to spore persistence in the lung. One mechanism is 
the association with the lung epithelium. We demonstrated using 
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  fluorescent microscopy that intranasal inoculation of mice with B. 
anthracis Sterne strain 7702 spores resulted in the observation that 
spores were inside lung epithelial cells in vivo and tightly 
associated with the alveolar epithelium up to 8 weeks post-
infection. We report that ~8% of spores found in the lung were 
associated with cytokeratin-positive epithelial cells at 4 weeks 
post-infection. This percentage is similar to the spore association 
with alveolar macrophages and dendritic cells (CD11b+ or CD11c+) 
which was reported to be ~5%. Our results provided direct evidence 
that even in the presence of phagocytes, the lung epithelium is 
exploited by B. anthracis weeks post-infection. This data supports 
are previous in vitro and in vivo data that spores are internalized 
and survive in epithelial cells hours after infection [67, 68]. 
Findings that B. anthracis spores are found associated with the lung 
epithelium at a chronic stage of infection, suggests that spores 
internalized by epithelial cells may begin germination in vivo, 
which can lead to a recurrent infection. It was reported in mouse 
models, only a few organisms were required to cause infection if B. 
anthracis were introduced directly into the blood stream (LD50 6 – 25 
spores) [124]. Based on the percentage of intracellular spores we 
identified in epithelial cells, if even only a small number of them 
escape into the circulation, it would be sufficient to cause an 
infection.  
The precise germination location in vivo remains poorly 
defined. Many groups have accepted that germination does not readily 
occur in the lungs [77, 123]. However, we have previously 
demonstrated in translocation assays using an in vitro model of the 
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  alveolar epithelium that germinated spores/vegetative bacilli were 
recovered from the basolateral side of the epithelium despite the 
presence of germination inhibitors in the media, suggesting that 
germination occurred inside epithelial cells [68]. Also, findings by 
Sanz et al reported germination proceeded in the lung [77]. These 
studies raise the possibility that the lung epithelium not only acts 
as a portal for spore dissemination away from the lung and for spore 
persistence, but also provides a venue for spore germination. The 
use of germination defective mutants in this model would surely 
provide insight into the germination status of B. anthracis inside 
lung epithelial cells in vivo.  
Collectively, these data provides us with the understanding 
that spores target so far three types of host cells (i.e. lung 
epithelial cells, macrophages, and dendritic cells) for spore 
persistence. The mechanisms of how B. anthracis spores are 
internalized by epithelial cells [29, 125], as well as phagocytes 
[27, 28] are known. Entry into epithelial cells and phagocytes is 
mediated by B. anthracis BclA protein via different receptors (i.e. 
α2β1 and Mac-1, respectively) [27, 29]. In this study, we report 
that BclA-expressing strains are more likely to remain in the lung 
than spores that do not express BclA, suggesting that persistence is 
linked to the expression of BclA. This data and our finding that 
BclA mediates spore persistence have important implications to 
vaccine development.  
Vaccination remains the best method available for combating 
anthrax infections. The current anthrax vaccine is based on 
protective antigen (PA) and requires 6 injections given over 18 
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  months followed by annual boosters. Developing new and improved 
vaccines that require shorter administration time and more 
convenient administration routes is needed and is being pursued by 
multiple research groups. BclA is the major and the most exposed 
molecule on the surface of B. anthracis spores [15] and it has been 
a topic of investigation for many years. Studies have described its 
assembly process and timing [13, 26, 126], N-terminal cleavage 
events [23], covalent attachment to the basal layer by BxpB [127], 
and its association into large molecular weight complexes during 
exosporium assembly [128]. BclA belongs to a family of proteins 
called bacterial collagens, which also includes Scls in Group A 
streptococci [129] and PclA in Streptococcus pneumoniae [130]. 
Proteins containing collagen-like regions are recently being 
explored in prokaryotes and understanding the functions of BclA will 
have implications to other members of the bacterial collagen family. 
It seems that what we know about BclA is perhaps the crest of a 
whole new wave of information. Importantly, we want to understand 
how beneficial is the presence of BclA on the spore surface to the 
intracellular survival of B. anthracis spores in vivo. Other 
exosporium-containing spores, such as B. cereus contain BclA on its 
spore surface [131]. It would be interesting to determine if BclA 
protein on B. cereus or other similar bacterial collagen proteins 
(i.e. Sc1s) can mediate persistence of bacteria in mice similar to 
BclA from B. anthracis. Several animal studies have demonstrated 
that immunization with BclA either provided protection or improved 
the protective efficacy of PA against lethal challenges with B. 
anthracis spores [105, 132-134]. We question then, will BclA provide 
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  better protection not only against acute infection but also spore 
persistence? The results from this study encourage future studies to 
determine the protective efficacy of recombinant fragments of BclA 
in long-term anthrax infections.  
We also revealed from our model that spore persistence might 
involve an immune evasion/suppression mechanism. The interactions 
between the host’s immune system and spores are also an important 
area of anthrax research. Therefore, our findings will surely 
improve our understanding of spores with the host immune system. We 
know that spores are capable of activating TLR2 and MyD88 signaling 
[30], inducing inflammatory cytokine production (i.e. IL-12 and 
IFNγ) [31, 32], activating natural killer cells [33, 34], and 
initiating the classical complement pathway via a direct interaction 
with BclA and Clq [35], but how these molecular pathways and host 
protein associations influence the ways in which spores survive 
longer in the infected host is not clear.  
We report that the very mild inflammation and pathology 
observed in the lung is indicative of a subdued immune reaction to 
B. anthracis spores. These findings suggest that the subdued immune 
response may be due to an active suppression mechanism of B. 
anthracis rather than passive inactivity of spores. We demonstrated 
that the anthrax toxins, in particular lethal factor, a major immune 
suppressor of B. anthracis did not play a role in spore persistence 
in the lung. This implies that B. anthracis spore surface components 
might contribute to this mechanism. We speculate that the presence 
of BclA on spores may play a role in immune evasion, thus preventing 
spores from being efficiently cleared by the host. From our in vitro 
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  data, BclA was identified as a factor H (fH) binding surface protein 
of B. anthracis. B. anthracis spores were able to recruit fH both 
from human and mouse serum and in a purified form, and this was 
mediated by BclA. We concluded that the B. anthracis-fH interaction 
was direct and independent of other serum proteins. It is this 
direct recruitment that may lead to the suppression of complement 
activation on the spores’ surface, akin to fH binding to host self-
surfaces.  
In mapping the regions involved on BclA for fH binding, we 
identified two binding sites. Both the CTD and CLR domains of BclA 
bound equally well to fH using different approaches to determine fH 
binding. We believe it is possible to have multiple binding sites on 
BclA for fH interaction. Borrelia hermsii CRASP-1 protein was 
reported to require both N- and C-terminal domains for binding to fH 
[135]. S. pyogenes, Fba protein contained a major fH binding site 
(in the N-terminus coiled-coil domain), but also had a second weak 
binding site in the C-terminus [136]. In future work, inhibition 
assays utilizing rBclACTD and spores expressing the CLR of BclA will 
be evaluated to determine the relevance of two binding sites. As 
reported in the study, we were unsuccessful at synthesizing a gene 
for the CLR and therefore could not obtain a recombinant protein. 
However, near the end of this study we were able to obtain a 
commercially constructed CLR gene product, which will then be used 
to generate a recombinant protein of this region for future studies. 
Furthermore, to have a better understanding about the regions 
of BclA that are important for fH binding, we performed sequence 
alignments with the sequence of BclA (CAD56870.1; B. anthracis 
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  Sterne Strain) to that of several known fH-binding proteins that 
have been described for various microbial pathogens. From the 
sequence alignments we found that the BclA protein had no 
significant similarity to any of the following fH-binding proteins 
(Yad A, PspC, CRASP 1 and 2, SdrE, Sbi, Hic, LfhA, Por1A, Tuf, OmpA, 
FhBp, and FhbB). Also, no other sequence homologies between fH-
binding proteins from different species have been reported. There 
have been only a few specific sequences identified for fH binding 
sites among the fH-binding proteins. In S. pyogenes, the major fH-
binding site of Fba was determined to be YKQKIKTAPDKDKLLF in the N-
terminus domain [136]. Similarly, a positively charged fH-binding 
site is found in the C-terminus domain of CRASP-3 of B. burgdorferi 
(LEVLKKNLK) [137]. A negatively charged binding site and hydrophobic 
interactions have been reported for PspC of S. pnuemoniae [53]. The 
Scl1 protein of Group A Streptococci, which also forms collagen 
triple helices similar to BclA, was reported to bind to fH [138]. 
However, a motif in the Scl1 V-region seemed to be involved in 
binding to fH and manipulation of the CLR did not alter the ligand-
binding properties [138]. These studies and other reports suggest 
that there is so far no commonality (in particular, sequence motifs) 
among the regions on fH-binding proteins that are involved in fH 
binding. It is possible that the conformation and structure of the 
respective fH-binding proteins influence the way they associate with 
fH. Therefore, we expect that the regions/structure of BclA involved 
in this interaction will be unique to B. anthracis. In order to 
further elucidate the binding sites of BclA, future work will 
include the generation of truncated fragments of both the CLR and 
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  CTD domains to define the residues that are important for binding to 
fH.  
To further characterize this interaction we anticipate to map 
the region in fH recognized by BclA. Multiple groups have expressed 
fragments containing different SCRs or mutations as recombinant 
proteins. In general, the baculovirus expression system in the 
insect cell line Sf9 has been commonly used to produce fH fragments. 
Binding of fH fragments to rBclA and to spores expressing full-
length or specific regions of BclA will be determined. The majority 
of fH-binding proteins have been described to bind to domains 19 – 
20 on fH [37]. A few have been described for interaction on heparin 
(SCR7) and C3b (6 – 8 and 19 – 20) binding sites, including M 
proteins and Fba of S. pyogenes, PorB 1A of N. gonorrhoeae, Ail of 
Y. enterocolitica, Tuf of P. aeruginosa, and Sbi of S. aureus [37]. 
For B. anthracis, our results indicate that BclA protein does not 
interact on heparin or C3b binding sites at the concentrations 
tested, but further experiments are needed to exclude these sites. 
It is also possible that the interaction can occur with the entire 
length of fH. Studies to elucidate the regions on fH are currently 
underway in our laboratory. 
 The consequences of the interaction between BclA-fH are vital 
to our general understanding on how microbial pathogens evade the 
host immune system to cause infection. The more we acquire 
information about the specific details of these mechanisms of host 
evasion by pathogens, then the better we can treat, diagnose, and 
prevent infections. FH is one of the most important complement 
inhibitors. The ability of fH to recognize specific markers on host 
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  cells is extremely important for limiting complement-mediated immune 
responses to self-surfaces. This is supported by clinical evidence 
showing that mutations or polymorphisms that affect fH recognition 
of host cells are associated with severe human diseases due to 
abnormal complement activation. The ability to recruit fH has been 
demonstrated in a wide range of microbial pathogens [37], including 
B. anthracis. This suggests that interaction with fH is a general 
microbial immune evasion strategy. For Gram-positive bacteria, the 
ability to bind complement inhibitors (e.g. fH and C4BP) is 
essential for evading opsonophagocytic killing by the complement 
cascade. Our findings indicate that BclA and most likely the fH-
binding portion of BclA are important for survival and persistence 
of spores in the mouse lung. This suggests that even for resilient 
organisms as spores, binding to fH can offer a survival advantage.  
Because BclA is only expressed on the surface of spores and is 
absent in vegetative cells [15], we focused on determining the 
effect of fH binding on spore persistence. The precise biological 
consequences of this interaction was investigated in this project by 
examining complement activation on the spore surface and spore 
persistence in the lungs of mice with spores that expressed BclA 
protein and were known fH-binders. In regards to the role fH plays 
in persistence, we showed that spores that can bind fH could remain 
in the lungs of mice significantly better than spores that were not 
able to bind fH. Furthermore, the activities of C1q were not 
involved in spore persistence. These findings highlight in an 
indirect way the possibility that the fH binding ability by BclA on 
these spores is contributing to the length of time these spores 
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  remain in the mouse lung compared to spores that cannot bind to fH. 
Because this is the case, we believe that BclA recruitment of fH 
could allow immune evasion during early stages of infection (at 
least partially), which could potentially lead to increased 
persistence in the host. Unfortunately, we were unable to utilize 
Cfh-/- mice since they have uncontrollable C3 activation resulting in 
C3 depletion. In general, evaluating the role fH plays in vivo is 
difficult and providing direct evidence is a challenge. 
Nevertheless, one way to determine specifically the role of BclA-fH 
binding in spore survival and persistence in mice is to generate B. 
anthracis spores specifically expressing only the fH-binding 
function of BclA and spores that carry mutations in the respective 
binding sites. Comparison of results from mice infected with these 
isogenic mutants will provide us a better understanding of fH 
recruitment by these spores. Other ways may include utilizing 
exogenous fH or inhibitors of fH-binding sites and priming B. 
anthracis spore strains with these molecules to block their 
interaction in vivo. FH present on the anthracis surface at the time 
of infection may appear to promote a more pronounced bacterial 
persistence and/or blocking of fH-binding sites on spores may result 
in a greater level of bacterial clearance in the host. These studies 
would have to be carried out to further understand the biological 
significance of fH recruitment by B. anthracis spores.  
Moreover, we found that BclA-expressing strains were able to 
suppress complement activation on their spore surface compared to a 
strain that lacked BclA protein. This data provided insight that 
BclA does not inhibit fH function and that BclA recruitment of fH 
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  likely serves to suppress complement activation, similar to what has 
been reported for other microbial fH-binding proteins. 
Our finding that BclA binds fH also has implications to vaccine 
development for anthrax infections. If BclA binding to fH is a 
mechanism for complement suppression and spore persistence in the 
lung, then we wonder if immunization with BclA, particularly the fH-
binding region of BclA, can protect against both acute and 
persistent infections. Results from studies performed with Neisseria 
meningitides indicate that vaccines based on the fH-binding region 
have broad protective efficacy against meningococcal diseases [139-
141]. This is encouraging and studies in our lab will be carried out 
to investigate the protective efficacy of BclA in anthrax 
infections.  
 The ability of B. anthracis spores to recruit fH warrants 
further attention because it is also likely that binding to fH 
influences the molecular pathways that enable B. anthracis to adhere 
and be phagocytosed by host cells. Besides its complement regulator 
activity, fH has been reported to play a role in the adhesion and 
entry into host cells by microbial pathogens. For example, S. 
pneumoniae, PspC protein recruitment of fH was shown to increase the 
attachment of pneumococci to host cells and increase the number of 
internalized bacteria [54]. In general, fH can bind via an RGD 
sequence of SCR4 to host cells [142]. Also, studies have reported 
that polymorphonuclear cells can bind immobilized fH via integrin 
CD11b/CD18 (CR3 receptor) [143]. This is interesting because B. 
anthracis spores are known to enter macrophages via the same 
receptor through BclA [27]. Studies from our group have shown that 
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  spores expressing BclA or fragments of BclA are more likely to be 
phagocytosed by macrophages and survive phagocytosis than spores 
that lack expression of BclA (unpublished, Chunfang Gu). It is not 
clear if the fH binding function of BclA plays a role in 
phagocytosis (or entry into other host cells, such as epithelial) 
and in intracellular survival. This will be determined in future 
investigations. Further efforts to identify the roles of fH 
recruitment by B. anthracis spores will bring us closer to a better 
understanding of the versatile roles played by fH in both health and 
disease and that of B. anthracis spores in anthrax infections.  
 Importantly, we demonstrated that the deletion mutant of BclA 
had a low level of fH binding, suggesting that proteins exposed on 
the surface of these spores in the absence of BclA are likely to 
interact with fH. The exosporium is composed of >20 proteins. Using 
a systematic approach, we could eliminate each one of these proteins 
from spores and/or generate recombinant proteins and evaluate fH-
binding. This will allow us to identify other proteins involved in 
fH binding on the BclA deletion mutant that would otherwise be 
masked by BclA. There are also several other complement proteins 
besides fH that will be evaluated for binding to spores. These 
include C4BP, an inhibitor of both classical and lectin pathways; 
FHL-1, an alternative splicing product of fH; fH-related proteins; 
and C3. The finding that spores may also bind to one or more of 
these proteins will surely expand our knowledge on the interactions 
between B. anthracis and the complement system.  
In summary, this is the first report to determine mechanisms of 
B. anthracis persistence and the first demonstration that B. 
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  anthracis spores can interact with host complement regulator fH 
(Model illustrated in Fig. 33). The data presented here have 
provided a step forward in understanding more about the persistence 
of spores adding to the theories that the asynchronous germination 
and/or the dormant and resilient properties of spores contributed to 
this persistent phenomenon. Medical literature on anthrax does not 
include any findings regarding long-term complications in infected 
individuals. Therefore, information gained in this study will be 
valuable to patients, military personnel, and health care workers, 
in addition to, the planning of the public health response in the 
event of a bioterrorist attack involving inhalational anthrax. The 
progress in our understanding of the factors involved in persistence 
and the interactions between B. anthracis and the host immune system 
(in particular the complement system) should greatly improve our 
ability to design safe and efficient vaccines. From a broader point 
of view, persistence is an important issue concerning a variety of 
microbial infections (e.g. uropathogenic E. coli, H. pylori, Group A 
streptococci [59, 63]). Persistence in vivo not only increases the 
number of hospital visits and health care costs, but also exposes 
the host body to prolonged stress and inflammation, raising the risk 
for other types of diseases, such as rheumatism and cancer. 
Moreover, by studying how microbial pathogens subvert the host 
defense system is critical to contemplating the fundamental 
properties of microbial pathogenesis and developing/improving on 
preventatives and therapeutics against these infections. Our 
mechanistic studies will have broad implications to a large number 
of clinically important microbial pathogens, as well as, our  
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  understanding of how the respiratory system functions under 
microbial challenge. Collectively, this work has provided precedence 
for future work related to the post-exposure prophylaxis regimens of 
B. anthracis.   
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